FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT
20240115744 ยท 2024-04-11
Inventors
Cpc classification
A61K51/088
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
G01N33/86
PHYSICS
International classification
A61K51/08
HUMAN NECESSITIES
Abstract
This disclosure relates to compounds of Formula IV: for fibrin imaging, wherein the compounds comprise an imaging or therapeutic radioisotope.
Claims
1. A compound of Formula IV: ##STR00171## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope; C.sup.4 is a chelating moiety selected from the group consisting of: ##STR00172## ##STR00173## ##STR00174## ##STR00175## ##STR00176## ##STR00177## ##STR00178## ##STR00179## ##STR00180## ##STR00181## ##STR00182## ##STR00183## CP.sup.4 is a fibrin-binding peptide; AA is the N-terminal amino acid of the fibrin-binding peptide; L.sup.4 is a linker; y is an integer selected from 0 or 1; and z is an integer selected from 0 or 1.
2. The compound of claim 1, wherein R.sup.4 is a radioisotope selected from a therapeutic radioisotope and a radioisotope capable of detection using a nuclear imaging technique.
3. The compound of claim 2, wherein the radioisotope capable of detection using a nuclear imaging technique is a positron emitting isotope or a radioisotope suitable for single-photon emission computerized tomography (SPECT) imaging.
4. The compound of claim 3, wherein the positron emitting isotope is selected from the group consisting of fluorine-18, aluminum fluoride (Al.sup.18F), scandium-43, scandium-44, manganese-51, manganese-52, copper-60, copper-61, copper-62, copper-64, gallium-68, yttrium-86, zirconium-89, iodine-124, terbium-149, and terbium-152.
5. The compound of claim 3, wherein the radioisotope suitable for SPECT imaging is selected from the group consisting of gallium-67, technetium-99m, indium-111, iodine-123, iodine-125, terbium-155, and lead-203.
6. The compound of claim 2, wherein the therapeutic radioisotope is selected from the group consisting of scandium-47, copper-67, yttrium-90, iodine-131, samarium-153, terbium-161, holmium-166, lutetium-177, rhenium-188, astatine-211, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227.
7. The compound of any one of claims 1 to 6, wherein AA-CP.sup.4 is a fibrin-binding peptide comprising a sequence having at least 80% sequence identity to the polypeptide of SEQ ID NO:1: TABLE-US-00044 (SEQIDNO:1) -y*-X.sup.1-C-Hyp-Y(3-Cl)-X.sup.2-L-C-X.sup.3-I-X.sup.4- wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently any amino acid; and y* is L-tyrosine or D-tyrosine.
8. The compound of any one of claims 1 to 6, wherein AA-CP.sup.4 is a fibrin-binding peptide comprising a polypeptide having at least 80% sequence identity to a polypeptide selected from the group consisting of: TABLE-US-00045 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
9. The compound of any one of claims 1 to 6, wherein AA-CP.sup.4 is a fibrin-binding peptide having at least 80% sequence identity to a polypeptide selected from the group consisting of: TABLE-US-00046 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
10. The compound of any one of claims 1 to 6, wherein AA-CP.sup.4 is a fibrin-binding peptide having at least 80% sequence identity to a polypeptide selected from the group consisting of: TABLE-US-00047 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-
11. The compound of any one of claims 1 to 6, wherein AA-CP.sup.4 is a fibrin-binding peptide having at least 80% sequence identity to a polypeptide of: TABLE-US-00048 SEQID NO: Sequence 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-
12. The compound of any one of claims 1 to 11, wherein C.sup.4 is selected from the group consisting of: ##STR00184##
13. The compound of claim 12, wherein C.sup.4 is ##STR00185##
14. The compound of any one of claims 1 to 11, wherein C.sup.4 is selected from the group consisting of: ##STR00186## ##STR00187## ##STR00188##
15. The compound of any one of claims 1 to 11, wherein C.sup.4 is selected from the group consisting of: ##STR00189## ##STR00190##
16. The compound of any one of claims 1 to 15, wherein y is 1.
17. The compound of any one of claims 1 to 11, wherein y is 0.
18. The compound of any one of claims 1 to 17, wherein L.sup.4 is pyridinyl or (pyridinyl)-C(O).
19. The compound of any one of claims 1 to 18, wherein z is 1.
20. The compound of any one of claims 1 to 17, wherein z is 0.
21. The compound of any one of claims 1 to 11, wherein y is 1 and z is 0.
22. The compound of any one of claims 1 to 11, wherein y is 1 and z is 1.
23. The compound of any one of claims 1 to 11, wherein y is 0 and z is 0.
24. The compound of any one of claims 1 to 11, wherein y is 0 and z is 1.
25. The compound of claim 1, wherein the compound of Formula IV is a compound of Formula IVa: ##STR00191## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope that is capable of being chelated by the chelating moiety C.sup.4.
26. The compound of claim 25, wherein R.sup.4 is selected from the group consisting of aluminum-fluoride (Al.sup.18F), scandium-43, scandium-44, scandium-47, manganese-51, manganese-52, copper-60, copper-61, copper-62, copper-64, copper-67, gallium-67, gallium-68, yttrium-86, zirconium-89, technetium-99m, yttrium-90, indium-111, terbium-149, terbium-152, samarium-153, terbium-155, terbium-161, holmium-166, lutetium-177, rhenium-188, lead-203, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227.
27. The compound of claim 1, wherein the compound of Formula IV is a compound of Formula IVb: ##STR00192## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope that is capable of covalently binding to the linker L.sup.4, the N-terminal amino acid of the fibrin-binding peptide AA, or both.
28. The compound of claim 1, wherein the compound of Formula IV is a compound of Formula IVc: ##STR00193## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope that is capable of covalently binding to the linker L.sup.4, the N-terminal amino acid of the fibrin-binding peptide AA, or both.
29. The compound of claim 1, wherein the compound of Formula IV is a compound of Formula IVd: ##STR00194## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope that is capable of covalently binding to the linker L.sup.4, the N-terminal amino acid of the fibrin-binding peptide AA, or both.
30. The compound of any one of claims 27-29, wherein R.sup.4 is selected from the group consisting of fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, and astatine-211.
31. The compound of any one of claims 1 to 11, wherein the compound is selected from the group consisting of: ##STR00195## ##STR00196## ##STR00197## ##STR00198## ##STR00199## ##STR00200## or a pharmaceutically acceptable salt thereof.
32. The compound of any one of claims 1 to 11, wherein the compound is selected from the group consisting of: ##STR00201## or a pharmaceutically acceptable salt thereof.
33. The compound of any one of claims 1 to 11, wherein the compound is: ##STR00202## or a pharmaceutically acceptable salt thereof.
34. The compound of any one of claims 1 to 11, wherein the compound is selected from the group consisting of: TABLE-US-00049 Com- pound N-terminus Sequence 25
35. A pharmaceutical composition comprising a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
36. The pharmaceutical composition of claim 35, comprising a radical scavenger.
37. The pharmaceutical composition of claim 36, wherein the radical scavenger is an antioxidant.
38. The pharmaceutical composition of claim 36 or 37, wherein the radical scavenger is selected from the group consisting of carnosic acid, green tea extract, apigenin, diosmine, rosmarinic acid, lipoic acid, beta carotene, L-ascorbic acid (vitamin C), N-acetyl cysteine (NAC), 6-tocopherol, rutin, amifostine, resveratrol, gentisic acid, and gallic acid.
39. A method of imaging fibrin in a mammal, the method comprising: a) administering to the mammal an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope capable of detection using a nuclear imaging technique; b) acquiring an image of the fibrin of the mammal using a nuclear imaging technique; c) acquiring an anatomical image of the mammal using magnetic resonance imaging or computed tomography; and d) overlaying the images of steps b) and c) to localize the image of fibrin within the anatomical image of the mammal.
40. The method of claim 39, wherein the presence of the fibrin is associated with neuroinflammation.
41. The method of claim 39 or 40, wherein the neuroinflammation is associated with Alzheimer's disease, multiple sclerosis, or traumatic brain injury.
42. The method of claim 39, further comprising: e) administering an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a therapeutic radioisotope.
43. The method of any one of claims 39 to 42, wherein the fibrin is present in a tumor.
44. The method of claim 43, wherein the tumor is cancerous.
45. The method of any one of claims 39 to 44, wherein the fibrin is present in a thrombus.
46. A method of treating a disease or condition associated with the presence of fibrin in a mammal, the method comprising: administering to the mammal an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a therapeutic radioisotope.
47. The method of claim 46, further comprising administering an amino acid solution.
48. The method of claim 47, wherein the amino acid solution comprises L-lysine, L-arginine, and pharmaceutically acceptable salts thereof, and combinations thereof.
49. The method of claim 48, wherein the amino acid solution comprises L-lysine HCl and L-arginine HCl.
50. The method of any one of claims 47 to 49, wherein the amino acid solution is administered prior to, concomitantly, after, or combinations thereof, administering the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.
51. The method of claim 50, wherein the amino acid solution is administered about 30 minutes prior to administering the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.
52. The method of claim 50 or 51, wherein the amino acid solution is administered concomitantly with administering the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.
53. The method of any one of claims 50 to 51, wherein the amino acid solution is administered about 30 minutes after administering the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.
54. The method of any one of claims 46 to 53, further comprising administering an antiemetic agent.
55. The method of claim 54, wherein the antiemetic agent is administered prior to, concomitantly, after, or combinations thereof, administering the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.
56. The method of claim 54 or 55, wherein the antiemetic agent is administered prior to, concomitantly, after, or combinations thereof, administering the amino acid solution.
57. The method of any one of claims 54 to 56, wherein the antiemetic agent is selected from the group consisting of 5-HT.sub.3 receptor antagonists, corticosteroids, neurokinin-1 (NK-1) receptor inhibitors, prochlorperazine, metoclorpramide, and cannabinoids.
58. The method of any one of claims 46 to 57, wherein the disease or condition associated with the presence of fibrin is cancer.
59. A method of treating cancer in a mammal, the method comprising: administering to the mammal an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a therapeutic radioisotope.
60. The method of claim 59, wherein the R.sup.4 that is a therapeutic radioisotope is selected from the group consisting of scandium-47, copper-67, yttrium-90, iodine-131, samarium-153, terbium-161, holmium-166, lutetium-177, rhenium-188, astatine-211, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227.
61. A method of detecting and treating a disease or condition associated with the presence of fibrin in a mammal, the method comprising: a) administering to the mammal an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope capable of detection using a nuclear imaging technique; b) acquiring an image of the fibrin of the mammal using a nuclear imaging technique; c) acquiring an anatomical image of the mammal using magnetic resonance imaging or computed tomography; d) overlaying the images of steps b) and c) to localize the image of fibrin within the anatomical image of the mammal; and e) administering an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a therapeutic radioisotope.
62. The method of claim 61, wherein the R.sup.4 that is a radioisotope capable of detection using a nuclear imaging technique is selected from the group consisting of fluorine-18, aluminum-fluoride (Al.sup.18F), scandium-43, scandium-44, copper-64, gallium-68, yttrium-86, zirconium-89, indium-111, iodine-123, iodine-124, terbium-149, terbium-152, terbium-155, and lead-203.
63. The method of claim 61 or 62, wherein the R.sup.4 that is a therapeutic radioisotope is selected from the group consisting of scandium-47, copper-67, yttrium-90, iodine-131, samarium-153, terbium-161, holmium-166, lutetium-177, rhenium-188, astatine-211, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227.
64. The method of any one of claims 61 to 63, further comprising administering an amino acid solution.
65. The method of claim 64, wherein the amino acid solution is administered prior to, concomitantly, after, or combinations thereof, administering the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof.
66. The method of any one of claims 61 to 65, further comprising administering an antiemetic agent.
67. The method of claim 66, wherein the antiemetic agent is administered prior to, concomitantly, after, or combinations thereof, administering the amino acid solution.
68. The method of any one of claims 61 to 67, wherein the disease or condition associated with the presence of fibrin is cancer.
69. A method of detecting and treating a disease or condition associated with the presence of fibrin in a mammal, the method comprising: a) administering to the mammal an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope capable of detection using a nuclear imaging technique selected from the group consisting of fluorine-18, copper-64, and gallium-68; b) acquiring an image of the fibrin of the mammal using a nuclear imaging technique; c) acquiring an anatomical image of the mammal using magnetic resonance imaging or computed tomography; d) overlaying the images of steps b) and c) to localize the image of fibrin within the anatomical image of the mammal; e) administering an effective amount of the pharmaceutical composition of any one of claims 35 to 37 or an effective amount of a compound of any one of claims 1 to 34, or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a therapeutic radioisotope selected from the group consisting of yttrium-90, lutetium-177, and actinium-225.
70. The method of claim 69, wherein the fibrin is present in a tumor.
71. The method of claim 70, wherein the tumor is cancerous.
72. A compound of Formula V: ##STR00217## or a pharmaceutically acceptable salt thereof, wherein: C.sup.4 is a chelating moiety; CP.sup.4 is a fibrin-binding peptide; AA is the N-terminal amino acid of the fibrin-binding peptide; L.sup.4 is a linker; y is an integer selected from 0 or 1; and z is an integer selected from 0 or 1.
73. The compound of compound of claim 72, wherein the compound of Formula IVe is a compound selected from the group consisting of: TABLE-US-00050 Com- pound Sequence 16 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-NH.sub.2 17 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-NH.sub.2 18 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q-NH.sub.2 19 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q-NH.sub.2 20 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 21 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-I-NH.sub.2 22 NODAGA-y-e-c-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 23 DOTAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 24 NOTA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2
Description
DESCRIPTION OF DRAWINGS
[0123]
[0124]
[0125]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132]
[0133]
[0134]
[0135]
[0136]
[0137]
[0138]
[0139]
[0140]
DETAILED DESCRIPTION
[0141] Thromboembolism plays a causative role in a number of potentially mortal cardiovascular events including stroke, coronary events, deep vein thrombosis, and pulmonary embolism. Of the nearly 795,000 strokes that occur in the U.S. each year, more than 80% of are ischemic, or thromboembolic, in nature. Treatment options are largely influenced by the anatomical location of the thrombus. Currently, multiple tests are required to assess each bodily region, for example, CT scans are used to locate lung thrombi, ultrasound tests can be employed for carotid arteries, and MRI analysis provides images of the heart chambers. Rapid location of the culprit clot(s) is necessary to determine proper therapeutic recourse.
[0142] Many approaches have been developed for the visualization of thrombi throughout the body. Fibrin is a particularly attractive target as it is present in all thrombi, including arterial, venous, and cardiac; it is not found in plasma, rendering the visualization technique highly specific; it is accessible in all active stages of clot development; and it is a high concentration target at about 20-100 ?M concentration. Fibrin-binding peptides can be functionalized, for example, with a chelating moiety that is able to chelate radioactive isotopes of various metals, including, but not limited to, actinium-225, bismuth-213, copper-64, copper-67, aluminum fluoride (Al.sup.18F), gallium-68, holmium-166, indium-111, lead-203, lead-212, lutetium-177, radium-223, samarium-153, scandium-43, scandium-44, scandium-47, terbium-149, terbium-152, terbium-155, terbium-161, thorium-227, yttrium-86, yttrium-90, and zirconium-89. Fibrin-binding peptides can also be functionalized with radioisotopes (including, but not limited to, .sup.18F, .sup.123I, .sup.124I, .sup.131I, and .sup.211At) through direct covalent modification or indirect covalent modification through a linker, but which does not require a chelating group. In some embodiments, the radioisotopes (which includes radioactive isotopes of metals) are useful as imaging or diagnostic agents. In some embodiments, the radioisotopes (including radioactive isotopes of metals) are useful as therapeutic agents. Provided herein are fibrin-specific compounds comprising one or more radioisotopes. Also provided are methods for imaging fibrin. Also provided are methods for treating diseases or disorders using the fibrin-specific compounds of the present disclosure as imaging or diagnostic agents, therapeutic agents, or both.
Definitions
[0143] Commonly used chemical abbreviations that are not explicitly defined in this disclosure may be found in The American Chemical Society Style Guide, Second Edition, American Chemical Society, Washington, D.C. (1997); 2001 Guidelines for Authors, J Org. Chem. 66(1), 24A (2001); and A Short Guide to Abbreviations and Their Use in Peptide Science, J. Peptide Sci. 5, 465-471 (1999).
[0144] As used herein, the term peptide refers to a chain of amino acids that is about 2 to about 25 amino acid residues in length. All peptide sequences herein are written from the N- to C-terminus. For any of the peptides described herein that contain two or more cysteine residues, it is understood that the cysteine residues can form one or more disulfide bonds under non-reducing conditions. Formation of a disulfide bond can result in the formulation of a cyclic peptide.
[0145] As used herein, the terms natural or naturally occurring amino acid refer to one of the twenty most common amino acids occurring in nature. Natural amino acids modified to provide a label for detection purposes (e.g., radioactive labels, optical labels, or dyes) are considered to be natural amino acids. Natural L amino acids are referred to by their standard one- or three-letter abbreviations. D amino acids are referred to using the lower-case convention for standard one-letter abbreviations, and the D- prefix convention for standard three-letter abbreviations.
[0146] As used herein, the terms chelator, chelating group and chelating moiety refer to a polydentate (multiple bonded) ligand that can form two or more separate coordinate bonds between the ligand and a single central atom, typically a metal ion. In some embodiments, the metal ion is a radioactive isotope of a metal. Examples of such metal ions include, but are not limited to, actinium-225, bismuth-213, copper-64, copper-67, gallium-68, holmium-166, indium-111, lead-203, lead-212, lutetium-177, radium-223, samarium-153, scandium-43, scandium-44, scandium-47, terbium-149, terbium-152, terbium-155, terbium-161, thorium-227, yttrium-86, yttrium-90, and zirconium-89.
[0147] As used herein, the terms radioactive isotope, radioisotope, radionuclide, and radioactive nuclide can be used interchangeably and refer to an unstable atom having excess nuclear energy; such excess energy can be emitted through one of three ways: emission from the nucleus as gamma radiation; transfer and release of one of its electrons as a conversion electron; or emission of a new particle (alpha or beta particle) from the nucleus. Such processes are known as radioactive decay of a radioisotope. Radioisotopes can be used for diagnostic imaging and for the treatment of a variety of diseases and conditions, including those described in the present disclosure.
[0148] As used herein, the terms target binding and binding refer to non-covalent interactions of a peptide or composition within a target. These non-covalent interactions are independent from one another and may be, inter alia, hydrophobic, hydrophilic, dipole-dipole, pi-stacking, hydrogen bonding, electrostatic associations, and/or Lewis acid-base interactions. The binding affinity for a target is expressed in terms of the equilibrium dissociation constant K.sub.d to the target under a defined set of conditions.
[0149] As used herein, the term purified refers to a peptide or compound that has been separated from either naturally occurring organic molecules with which it normally associates or, for a chemically-synthesized molecule, separated from other organic molecules present in the chemical synthesis. Typically, the polypeptide or compound is considered purified when it is at least 70% (e.g., at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%), by dry weight, free from any other proteins or organic molecules. The terms purified and isolated are used interchangeably herein.
[0150] The terms percent identity or identity in the context of two or more nucleic acids or polypeptides, refer to two or more sequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same. The percent identity can be measured using sequence comparison software or algorithms or by visual inspection.
[0151] In general, percent sequence identity is calculated by determining the number of matched positions in aligned nucleic acid or polypeptide sequences, dividing the number of matched positions by the total number of aligned nucleotides or amino acids, respectively, and multiplying by 100. A matched position refers to a position in which identical nucleotides or amino acids occur at the same position in aligned sequences. The total number of aligned nucleotides or amino acids refers to the minimum number of nucleotides or amino acids that are necessary to align the second sequence, and does not include alignment (e.g., forced alignment) with non-fibrin binding sequences. The total number of aligned nucleotides or amino acids may correspond to the entire sequence or may correspond to fragments of the full-length sequence.
[0152] Sequences can be aligned using the algorithm described by Altschul et al. (Nucleic Acids Res, 25:3389-3402, 1997) as incorporated into BLAST (basic local alignment search tool) programs, available at ncbi.nlm.nih.gov on the World Wide Web. BLAST searches or alignments can be performed to determine percent sequence identity between a nucleic acid or polypeptide and any other sequence or portion thereof using the Altschul et al. algorithm. BLASTN is the program used to align and compare the identity between nucleic acid sequences, while BLASTP is the program used to align and compare the identity between amino acid sequences. When utilizing BLAST programs to calculate the percent identity between a fibrin-binding sequence and another sequence, the default parameters of the respective programs are used.
[0153] Where values are described as ranges, it will be understood that such disclosure includes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated.
Compounds
[0154] Provided herein are compounds of Formula I:
[M.sup.1].sub.m-[C.sup.1].sub.n-[CP.sup.1]-[L.sup.1].sub.o-[C.sup.1].sub.p-[M.sup.1].sub.q(I)
or a pharmaceutically acceptable salt thereof, [0155] wherein each M.sup.1 is independently copper-64 or gallium-68; [0156] each C.sup.1 is a chelating moiety independently selected from the group consisting of:
##STR00062## ##STR00063## ##STR00064## [0157] CP.sup.1 is a fibrin-binding peptide; [0158] each L.sup.1 is independently a linker moiety; [0159] m is an integer selected from 0 to 5; [0160] n is an integer selected from 0 to 5; [0161] o is an integer selected from 0 to 5; [0162] p is an integer selected from 0 to 5; and [0163] q is an integer selected from 0 to 5.
[0164] In some embodiments of Formula I, each M.sup.1 is copper-64. In some embodiments of Formula I, each M.sup.1 is gallium-68.
[0165] In some embodiments of Formula I, each C.sup.1 is independently selected from the group consisting of:
##STR00065## ##STR00066##
[0166] In some embodiments of Formula I, C.sup.1 is NODAGA:
##STR00067##
[0167] In some embodiments of Formula I, each C.sup.1 is independently selected from the group consisting of:
##STR00068## ##STR00069##
[0168] In some embodiments of Formula I, CP.sup.1 is a fibrin-binding peptide comprising a sequence having at least 80% sequence identity to the polypeptide of SEQ ID NO:1: [0169] -y*-X.sup.1-C-Hyp-Y(3-Cl)-X.sup.2-L-CX.sup.3-IX.sup.4- (SEQ ID NO: 1)
wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently any amino acid; and y* is L-tyrosine or D-tyrosine. For example, CP.sup.1 is a fibrin-binding peptide comprising a sequence having at least 85%, at least 90%, at least 92% at least 95%, at least 98%, at least 99%, or 100% sequence identity to the polypeptide of SEQ ID NO:1. In some embodiments, CP.sup.1 is the polypeptide of SEQ ID NO:1 (i.e., it has 100% sequence identity).
[0170] In some embodiments, y* is L-tyrosine. In some embodiments, y* is D-tyrosine.
[0171] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr. In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from the D-configuration of the naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from D-Ala, D-Cys, D-Asp, D-Glu, D-Phe, D-His, D-Ile, D-Lys, D-Leu, D-Met, D-Asn, D-Pro, D-Gln, D-Arg, D-Ser, D-Thr, D-Val, D-Trp, and D-Tyr. In some embodiments, X.sup.1 is Glu. In some embodiments, X.sup.1 is D-His. In some embodiments, X.sup.2 is Gly. In some embodiments, X.sup.2 is Asp. In some embodiments, X.sup.2 is D-Asp. In some embodiments, X.sup.3 is His. In some embodiments, X.sup.3 is Tyr. In some embodiments, X.sup.4 is Gin. In some embodiments, X.sup.4 is D-Gin. In some embodiments, X.sup.4 is Leu. In some embodiments, X.sup.4 is D-Leu.
[0172] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from non-naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Hyp, D-Hyp, Tyr-3-Cl, and D-Tyr-3-Cl.
[0173] In some embodiments of Formula I, CP.sup.1 is a fibrin-binding peptide comprising a polypeptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00017 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0174] In some embodiments of Formula I, CP.sup.1 is a fibrin-binding peptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00018 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0175] In some embodiments of Formula I, each L.sup.1 is independently selected from the group consisting of:
##STR00070##
[0176] In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, o is 1. In some embodiments, o is 2. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, each of m, p, n, o, and q is 1. In some embodiments, each of m, p, n, o, and q is 2.
[0177] In some embodiments of Formula I, the compound is selected from the group consisting of:
##STR00071## ##STR00072##
or a pharmaceutically acceptable salt thereof.
[0178] In some embodiments of Formula I, the compound is selected from the group consisting of:
##STR00073## ##STR00074##
or a pharmaceutically acceptable salt thereof.
[0179] Also provided herein are compounds of Formula Ia:
[M.sup.1a]-[C.sup.1a]-[CP.sup.1a]-[M.sup.1a](Ia)
or a pharmaceutically acceptable salt thereof, [0180] wherein each M.sup.1a is independently copper-64 or gallium-68; [0181] C.sup.1a is a chelating moiety independently selected from the group consisting of:
##STR00075## ##STR00076## [0182] and CP.sup.1a is a fibrin-binding peptide.
[0183] In some embodiments of Formula Ia, each M.sup.1a is copper-64. In some embodiments of Formula Ia, each M.sup.1a is gallium-68.
[0184] In some embodiments of Formula Ia, C.sup.1a is NODAGA:
##STR00077##
[0185] In some embodiments of Formula Ia, CP.sup.1a is a fibrin-binding peptide comprising a sequence having at least 80% sequence identity to the polypeptide of SEQ ID NO: 1:
TABLE-US-00019 (SEQIDNO:1) -y*-X.sup.1-C-Hyp-Y(3-Cl)-X.sup.2-L-C-X.sup.3-I-X.sup.4-
wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently any amino acid; and y* is L-tyrosine or D-tyrosine. For example, CP.sup.1a is a fibrin-binding peptide comprising a sequence having at least 85%, at least 90%, at least 92% at least 95%, at least 98%, at least 99%, or 100% sequence identity to the polypeptide of SEQ ID NO:1. In some embodiments, CP.sup.1a is the polypeptide of SEQ ID NO:1 (i.e., it has 100% sequence identity).
[0186] In some embodiments, y* is L-tyrosine. In some embodiments, y* is D-tyrosine.
[0187] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr. In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from the D-configuration of the naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from D-Ala, D-Cys, D-Asp, D-Glu, D-Phe, D-His, D-Ile, D-Lys, D-Leu, D-Met, D-Asn, D-Pro, D-Gln, D-Arg, D-Ser, D-Thr, D-Val, D-Trp, and D-Tyr. In some embodiments, X.sup.1 is Glu. In some embodiments, X.sup.1 is D-His. In some embodiments, X.sup.2 is Gly. In some embodiments, X.sup.2 is Asp. In some embodiments, X.sup.2 is D-Asp. In some embodiments, X.sup.3 is His. In some embodiments, X.sup.3 is Tyr. In some embodiments, X.sup.4 is Gln. In some embodiments, X.sup.4 is D-Gln. In some embodiments, X.sup.4 is Leu. In some embodiments, X.sup.4 is D-Leu.
[0188] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from non-naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Hyp, D-Hyp, Tyr-3-Cl, and D-Tyr-3-Cl.
[0189] In some embodiments of Formula Ia, CP.sup.1a is a fibrin-binding peptide comprising a polypeptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00020 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0190] In some embodiments of Formula Ia, CP.sup.1a is a fibrin-binding peptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00021 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-c-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0191] Also provided herein are compounds of Formula Ib:
[M.sup.1b]-[C.sup.1b]-[CP.sup.1b]-[M.sup.1b](Ib)
or a pharmaceutically acceptable salt thereof,
[0192] wherein each M.sup.1b is independently copper-64 or gallium-68; [0193] C.sup.1b is NODAGA:
##STR00078##
and [0194] CP.sup.1b is a fibrin-binding peptide.
[0195] In some embodiments of Formula Ib, each M.sup.1b is copper-64. In some embodiments of Formula Ib, each M.sup.1b is gallium-68.
[0196] In some embodiments of Formula Ib, CP.sup.1b is a fibrin-binding peptide comprising a sequence having at least 80% sequence identity to the polypeptide of SEQ ID NO:1:
TABLE-US-00022 (SEQIDNO:1) -y*-X.sup.1-C-Hyp-Y(3-Cl)-X.sup.2-L-C-X.sup.3-I-X.sup.4-
wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently any amino acid; and y* is L-tyrosine or D-tyrosine. For example, CP.sup.1b is a fibrin-binding peptide comprising a sequence having at least 85%, at least 90%, at least 92% at least 95%, at least 98%, at least 99%, or 100% sequence identity to the polypeptide of SEQ ID NO:1. In some embodiments, CP.sup.1b is the polypeptide of SEQ ID NO:1 (i.e., it has 100% sequence identity).
[0197] In some embodiments, y* is L-tyrosine. In some embodiments, y* is D-tyrosine.
[0198] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr. In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from the D-configuration of the naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from D-Ala, D-Cys, D-Asp, D-Glu, D-Phe, D-His, D-Ile, D-Lys, D-Leu, D-Met, D-Asn, D-Pro, D-Gln, D-Arg, D-Ser, D-Thr, D-Val, D-Trp, and D-Tyr. In some embodiments, X.sup.1 is Glu. In some embodiments, X.sup.1 is D-His. In some embodiments, X.sup.2 is Gly. In some embodiments, X.sup.2 is Asp. In some embodiments, X.sup.2 is D-Asp. In some embodiments, X.sup.3 is His. In some embodiments, X.sup.3 is Tyr. In some embodiments, X.sup.4 is Gin. In some embodiments, X.sup.4 is D-Gin. In some embodiments, X.sup.4 is Leu. In some embodiments, X.sup.4 is D-Leu.
[0199] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from non-naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Hyp, D-Hyp, Tyr-3-Cl, and D-Tyr-3-Cl.
[0200] In some embodiments of Formula Ib, CP.sup.1b is a fibrin-binding peptide comprising a polypeptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00023 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0201] In some embodiments of Formula Ib, CP.sup.1b is a fibrin-binding peptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95% at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00024 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0202] Also provided herein are compounds of Formula IL:
[M.sup.2].sub.r-[C.sup.2].sub.s-[CP.sup.2]-[R.sup.2].sub.t(II)
or a pharmaceutically acceptable salt thereof, [0203] wherein each M.sup.2 is independently copper-64 or gallium-68; [0204] each C.sup.2 is independently a chelating moiety; [0205] CP.sup.2 is a fibrin-binding peptide; [0206] each R.sup.2 is independently an organic, non-chelating moiety; [0207] r is an integer selected from 0 to 5; [0208] s in an integer selected from 0 to 5; and [0209] t is an integer selected from 0 to 5.
[0210] In some embodiments of Formula II, each M.sup.2 is copper-64. In some embodiments of Formula II, each M.sup.2 is gallium-68.
[0211] In some embodiments of Formula II, each C.sup.2 is independently selected from the group consisting of:
##STR00079## ##STR00080##
[0212] In some embodiments of Formula II, C.sup.2 is NODAGA:
##STR00081##
[0213] In some embodiments of Formula II, each C.sup.2 is independently selected from the group consisting of:
##STR00082## ##STR00083##
[0214] In some embodiments of Formula II, CP.sup.2 is a fibrin-binding peptide comprising a sequence having at least 80% sequence identity to the polypeptide of SEQ ID NO:16:
TABLE-US-00025 (SEQIDNO:16) -y*-X.sup.5-C-Hyp-Y(3-Cl)-X.sup.6-L-C-X.sup.7-I-X.sup.8-
wherein each of X.sup.5, X.sup.6, X.sup.7, and X.sup.8 is independently any amino acid; and y* is L-tyrosine or D-tyrosine. For example, CP.sup.2 is a fibrin-binding peptide comprising a sequence having at least 85%, at least 90%, at least 92% at least 95%, at least 98%, at least 99%, or 100% sequence identity to the polypeptide of SEQ ID NO:16. In some embodiments, CP.sup.2 is a fibrin-binding peptide of SEQ ID NO:16 (i.e., having 100% sequence identity to SEQ ID NO:16).
[0215] In some embodiments, y* is L-tyrosine. In some embodiments, y* is D-tyrosine.
[0216] In some embodiments, each of X.sup.5, X.sup.6, X.sup.7, and X.sup.8 is independently selected from naturally occurring amino acids. For example, each of X.sup.5, X.sup.6, X.sup.7, and X.sup.8 is independently selected from Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr. In some embodiments, each of X.sup.5, X.sup.6, X.sup.7, and X.sup.8 is independently selected from the D-configuration of the naturally occurring amino acids. For example, each of X.sup.5, X.sup.6, X.sup.7, and X.sup.8 is independently selected from D-Ala, D-Cys, D-Asp, D-Glu, D-Phe, D-His, D-Ile, D-Lys, D-Leu, D-Met, D-Asn, D-Pro, D-Gln, D-Arg, D-Ser, D-Thr, D-Val, D-Trp, and D-Tyr. In some embodiments, X.sup.5 is Glu. In some embodiments, X.sup.5 is D-His. In some embodiments, X.sup.6 is Gly. In some embodiments, X.sup.6 is Asp. In some embodiments, X.sup.6 is D-Asp. In some embodiments, X.sup.7 is His. In some embodiments, X.sup.7 is Tyr. In some embodiments, X.sup.8 is Gln. In some embodiments, X.sup.8 is D-Gln. In some embodiments, X.sup.8 is Leu. In some embodiments, X.sup.8 is D-Leu.
[0217] In some embodiments, each of X.sup.5, X.sup.6, X.sup.7, and X.sup.8is independently selected from non-naturally occurring amino acids. For example, each of X.sup.5, X.sup.6, X.sup.7, and X.sup.8is independently selected from Hyp, D-Hyp, Tyr-3-Cl, and D-Tyr-3-Cl.
[0218] In some embodiments of Formula II, CP.sup.2 is a fibrin-binding peptide comprising a polypeptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00026 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0219] In some embodiments of Formula II, CP.sup.2 is a fibrin-binding peptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95% at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00027 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0220] In some embodiments of Formula II, each R.sup.2 is independently selected from the group consisting of N[(CH.sub.2).sub.aOR.sup.a].sub.2, NH(CH.sub.2).sub.aOR.sup.a, NH(CH.sub.2).sub.aOH, NH(CH.sub.2)CH.sub.3, N[(CH.sub.2).sub.aCH.sub.3], NH(CF.sub.2).sub.aCF.sub.3,
##STR00084##
OR.SUP.a., and
[0221] ##STR00085## [0222] wherein each R.sup.a is independently (C.sub.1-C.sub.6)alkyl; and [0223] a is an integer selected from 0 to 5.
[0224] In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, each of r, s, and t is 1. In some embodiments, each of r, s, and t is 2.
[0225] Also provided herein are compounds of Formula III:
[R.sup.3].sub.u-[CP.sup.3]-[C.sup.3].sub.v-[M.sup.3].sub.w(III)
or a pharmaceutically acceptable salt thereof, [0226] wherein each M.sup.3 is independently copper-64 or gallium-68; [0227] each C.sup.3 is a chelating moiety; [0228] CP.sup.3 is a fibrin-binding peptide; [0229] each R.sup.3 is independently an organic, non-chelating moiety; [0230] u is an integer selected from 0 to 5; [0231] v in an integer selected from 0 to 5; and [0232] w is an integer selected from 0 to 5.
[0233] In some embodiments of Formula III, each M.sup.3 is copper-64. In some embodiments of Formula III, each M.sup.3 is gallium-68.
[0234] In some embodiments of Formula III, each C.sup.3 is independently selected from the group consisting of:
##STR00086## ##STR00087##
[0235] In some embodiments of Formula III, C.sup.3 is NODAGA:
##STR00088##
[0236] In some embodiments of Formula III, each C.sup.3 is independently selected from the group consisting of:
##STR00089## ##STR00090##
[0237] In some embodiments of Formula III, CP.sup.3 is a fibrin-binding peptide comprising a sequence having at least 80% sequence identity to the polypeptide of SEQ ID NO:17:
TABLE-US-00028 (SEQIDNO:17) -y*-X.sup.9-C-Hyp-Y(3-Cl)-X.sup.10-L-C-X.sup.11-I-X.sup.12-
wherein each of X.sup.9, X.sup.10, X.sup.11, and X.sup.12 is independently any amino acid; and y* is L tyrosine or D-tyrosine. For example, CP.sup.3 is a fibrin-binding peptide comprising a sequence having at least 85%, at least 90%, at least 92% at least 95%, at least 98%, at least 99%, or 100% sequence identity to the polypeptide of SEQ ID NO:17. In some embodiments, CP.sup.3 is a fibrin-binding peptide of SEQ ID NO:17 (i.e., having 100% sequence identity to SEQ ID NO:17).
[0238] In some embodiments, y* is L-tyrosine. In some embodiments, y* is D-tyrosine.
[0239] In some embodiments, each of X.sup.9, X.sup.10, X.sup.11, and X.sup.12 is independently selected from naturally occurring amino acids. For example, each of X.sup.9, X.sup.10, X.sup.11, and X.sup.12 is independently selected from Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr. In some embodiments, each of X.sup.9, X.sup.10, X.sup.11, and X.sup.12 is independently selected from the D-configuration of the naturally occurring amino acids. For example, each of X.sup.9, X.sup.10, X.sup.11, and X.sup.12 is independently selected from D-Ala, D-Cys, D-Asp, D-Glu, D-Phe, D-His, D-Ile, D-Lys, D-Leu, D-Met, D-Asn, D-Pro, D-Gln, D-Arg, D-Ser, D-Thr, D-Val, D-Trp, and D-Tyr. In some embodiments, X.sup.9 is Glu. In some embodiments, X.sup.9 is D-His. In some embodiments, X .sup.10 is Gly. In some embodiments, X.sup.10 is Asp. In some embodiments, X.sup.10 is D-Asp. In some embodiments, X.sup.11 is His. In some embodiments, X.sup.11 is Tyr. In some embodiments, X.sup.12 is Gin. In some embodiments, X.sup.12 is D-Gln. In some embodiments, X.sup.12 is Leu. In some embodiments, X.sup.12 is D-Leu.
[0240] In some embodiments, each of X.sup.9, X.sup.10, X.sup.11, and X.sup.12 is independently selected from non-naturally occurring amino acids. For example, each of X.sup.9, X.sup.10, X.sup.11, and X.sup.12 is independently selected from Hyp, D-Hyp, Tyr-3-Cl, and D-Tyr-3-Cl.
[0241] In some embodiments of Formula III, CP.sup.3 is a fibrin-binding peptide comprising a polypeptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00029 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0242] In some embodiments of Formula III, CP.sup.3 is a fibrin-binding peptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99% or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00030 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0243] In some embodiments of Formula III, each R.sup.3 is independently selected from the group consisting of N[(CH.sub.2).sub.bOR.sup.b].sub.2, NH(CH.sub.2).sub.bOR.sup.b, NH(CH.sub.2).sub.bOH, NH(CH.sub.2)CH.sub.3, N[(CH.sub.2).sub.bCH.sub.3], NH(CF.sub.2).sub.bCF.sub.3,
##STR00091##
OR.SUB.b., and
[0244] ##STR00092## [0245] wherein each R.sup.b is independently (C.sub.1-C.sub.6)alkyl; and [0246] b is an integer selected from 0 to 5.
[0247] In some embodiments, u is 1. In some embodiments, u is 2. In some embodiments, v is 1. In some embodiments, v is 2. In some embodiments, w is 1. In some embodiments, w is 2. In some embodiments, each of u, v, and w is 1. In some embodiments, each of u, v, and w is 2.
[0248] Also provided are compounds of Formula IV:
##STR00093##
or a pharmaceutically acceptable salt thereof, [0249] wherein R.sup.4 is a radioisotope; [0250] C.sup.4 is a chelating moiety selected from the group consisting of:
##STR00094## ##STR00095## ##STR00096## ##STR00097## ##STR00098## ##STR00099## ##STR00100## ##STR00101## ##STR00102## ##STR00103## ##STR00104## ##STR00105## [0251] CP.sup.4 is a fibrin-binding peptide; [0252] AA is the N-terminal amino acid of the fibrin-binding peptide; [0253] L.sup.4 is a linker; [0254] y is an integer selected from 0 and 1; and [0255] z is an integer selected from 0 and 1.
[0256] In some embodiments of Formula IV, R.sup.4 is a radioisotope selected from a therapeutic radioisotope and a radioisotope capable of detection using a nuclear imaging technique. In some embodiments, R.sup.4 is selected from the group consisting of fluorine-18, aluminum fluoride (Al.sup.18F), scandium-43, scandium-44, scandium-47, manganese-51, manganese-52, copper-60, copper-61, copper-62, copper-64, copper-67, gallium-67, gallium-68, yttrium-86, zirconium-89, technetium-99m, yttrium-90, indium-111, iodine-123, iodine-124, iodine-125, iodine-131, terbium-149, terbium-152, samarium-153, terbium-155, terbium-161, holmium-166, lutetium-177, rhenium-188, lead-203, astatine-211, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227.
[0257] In some embodiments of Formula IV, R.sup.4 is a radioisotope that is a therapeutic radioisotope. In some embodiments, the therapeutic radioisotope is selected from the group consisting of scandium-47, copper-67, yttrium-90, iodine-131, samarium-153, terbium-161, holmium-166, lutetium-177, rhenium-188, astatine-211, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227. In some embodiments, the therapeutic isotope is selected from the group consisting of yttrium-90, lutetium-177, and actinium-225. In some embodiments, the therapeutic isotope is yttrium-90. In some embodiments, the therapeutic radioisotope is lutetium-177. In some embodiments, the therapeutic radioisotope is actinium-225.
[0258] In some embodiments of Formula IV, R.sup.4 is a radioisotope capable of detection using a nuclear imaging technique. In some embodiments, the radioisotope is a positron emitting isotope. In some embodiments, the positron emitting isotope is selected from the group consisting of fluorine-18, aluminum fluoride (Al.sup.18F), scandium-43, scandium-44, manganese-51, manganese-52, copper-60, copper-61, copper-62, copper-64, gallium-68, yttrium-86, zirconium-89, iodine-124, terbium-149, and terbium-152. In some embodiments, the positron emitting isotope is selected from the group consisting of fluorine-18, copper-64, and gallium-68. In some embodiments, the positron emitting isotope is fluorine-18. In some embodiments, the positron emitting isotope is copper-64. In some embodiments, the positron emitting isotope is gallium-68. In some embodiments, the positron emitting isotope is copper-64. In some embodiments, the positron emitting isotope is gallium-68. In some embodiments, the radioisotope is a radioisotope suitable for SPECT imaging. In some embodiments, the radioisotope suitable for SPECT imaging is selected from the group consisting of gallium-67, technetium-99m, indium-111, iodine-123, iodine-125, terbium-155, and lead-203.
[0259] In some embodiments of Formula IV, C.sup.4 is selected from the group consisting of:
##STR00106## ##STR00107##
[0260] In some embodiments of Formula IV, C.sup.4 is NODAGA:
##STR00108##
[0261] In some embodiments of Formula IV, C.sup.4 is selected from the group consisting of:
##STR00109## ##STR00110##
[0262] In some embodiments, C.sup.4 is selected from the group consisting of:
##STR00111## ##STR00112## ##STR00113##
[0263] In some embodiments of Formula IV, AA-CP.sup.4 is a fibrin-binding peptide comprising a sequence having at least 80% sequence identity to the polypeptide of SEQ ID NO: 1:
TABLE-US-00031 (SEQIDNO:1) -y*-X.sup.1-C-Hyp-Y(3-Cl)-X.sup.2-L-C-X.sup.3-I-X.sup.4-
wherein each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently any amino acid; y* is L-tyrosine or D-tyrosine; and AA represents the N-terminal amino acid. For example, AA-CP.sup.4 is a fibrin-binding peptide comprising a sequence having at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to the polypeptide of SEQ ID NO:1. In some embodiments, AA-CP.sup.4 is the polypeptide of SEQ ID NO:1 (i.e., it has 100% sequence identity).
[0264] In some embodiments, y* is L-tyrosine. In some embodiments, y* is D-tyrosine.
[0265] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr. In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from the D-configuration of the naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from D-Ala, D-Cys, D-Asp, D-Glu, D-Phe, D-His, D-Ile, D-Lys, D-Leu, D-Met, D-Asn, D-Pro, D-Gln, D-Arg, D-Ser, D-Thr, D-Val, D-Trp, and D-Tyr. In some embodiments, X.sup.1 is Glu. In some embodiments, X.sup.1 is D-His. In some embodiments, X.sup.2 is Gly. In some embodiments, X.sup.2 is Asp. In some embodiments, X.sup.2 is D-Asp. In some embodiments, X.sup.3 is His. In some embodiments, X.sup.3 is Tyr. In some embodiments, X.sup.4 is Gln. In some embodiments, X.sup.4 is D-Gln. In some embodiments, X.sup.4 is Leu. In some embodiments, X.sup.4 is D-Leu.
[0266] In some embodiments, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from non-naturally occurring amino acids. For example, each of X.sup.1, X.sup.2, X.sup.3, and X.sup.4 is independently selected from Hyp, D-Hyp, Tyr-3-Cl, and D-Tyr-3-Cl.
[0267] In some embodiments of Formula IV, AA-CP.sup.4 is a fibrin-binding peptide, wherein AA represents the N-terminal amino acid, comprising a polypeptide having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00032 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0268] In some embodiments of Formula IV, AA-CP.sup.4 is a fibrin-binding peptide, wherein AA represents the N-terminal amino acid, having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00033 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 6 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 7 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 8 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 9 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 10 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-l- 11 -y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 12 -Y-e-C-Hyp-Y(3-Cl)-D-L-C-Y-I-Q- 13 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-q- 14 -Y-e-C-Hyp-Y(3-Cl)-d-L-C-Y-I-Q- 15 -Y-h-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-
[0269] In some embodiments of Formula IV, AA-CP.sup.4 is a fibrin-binding peptide, wherein AA represents the N-terminal amino acid, having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00034 SEQID NO: Sequence 2 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 3 -y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-l- 4 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-
[0270] In some embodiments of Formula IV, AA-CP.sup.4 is a fibrin-binding peptide, wherein AA represents the N-terminal amino acid, having at least 80% (e.g., at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, at least 99%, or 100%) sequence identity to a polypeptide selected from the group consisting of:
TABLE-US-00035 SEQID NO: Sequence 5 -Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-
In some embodiments of Formula IV, the [(L.sup.4).sub.z-(AA)] moiety represents the N-terminal amino acid of the fibrin-binding peptide CP.sup.4 optionally modified with a linker, where AA is the N-terminal amino acid of the fibrin-binding peptide and L.sup.4 is the optional linker. The linker L.sup.4 can be any compound comprising a functional group that can form a covalent bond with the N-terminus of an amino acid, such as the N-terminus of the fibrin-binding peptide CP.sup.4.
[0271] In some embodiments, L.sup.4 is selected from the group consisting of C.sub.1-C.sub.6 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl, C.sub.1-C.sub.6 alkyl-C(O), 6-10 membered aryl-C(O), and 5-10 membered heteroaryl-C(O). In some embodiments, L.sup.4 is 5-6 membered heteroaryl. In some embodiments, L.sup.4 is a pyridinyl group. In some embodiments, L.sup.4 is 5-6 membered heteroaryl-C(O). In some embodiments, L.sup.4 is (pyridinyl)-C(O). In some embodiments, L.sup.4 is (pyridin-3-yl)-C(O).
[0272] In some embodiments of the compound of Formula IV, the [(C.sup.4).sub.y(R.sup.4))] moiety binds to the [(L.sup.4).sub.z-(AA)] moiety through the L.sup.4 group, where the chelating moiety C.sup.4 binds to the L.sup.4 group. In some embodiments, the [(C.sup.4).sub.y(R.sup.4))] moiety binds to the [(L.sup.4).sub.z-(AA)] moiety through the L.sup.4 group, where the radioisotope R.sup.4 binds to the L.sup.4 group. In some embodiments, the [(C.sup.4).sub.y(R.sup.4))] moiety binds to the [(L.sup.4).sub.z-(AA)] moiety through the AA group, where the radioisotope R.sup.4 binds to the AA group. In some embodiments, the [(C.sup.4).sub.y(R.sup.4))] moiety binds to the [(L.sup.4).sub.z-(AA)] moiety through the AA group, where the chelating moiety C.sup.4 binds to the AA group.
[0273] In some embodiments of Formula IV, y is 0. In some embodiments, y is 1.
[0274] In some embodiments of Formula IV, z is 0. In some embodiments, z is 1.
[0275] In some embodiments of Formula IV, y is 0 and z is 0. In some embodiments, y is 0 and z is 1. In some embodiments, 1 is y, and z is 0. In some embodiments, 1 is y and z is 1.
[0276] In some embodiments, the compound of Formula IV is a compound of Formula IVa:
##STR00114##
or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope that is capable of being chelated by the chelating moiety C.sup.4.
[0277] In some embodiments, R.sup.4 is selected from the group consisting of aluminum-fluoride (Al.sup.18F), scandium-43, scandium-44, scandium-47, manganese-51, manganese-52, copper-60, copper-61, copper-62, copper-64, copper-67, gallium-67, gallium-68, yttrium-86, zirconium-89, technetium-99m, yttrium-90, indium-111, terbium-149, terbium-152, samarium-153, terbium-155, terbium-161, holmium-166, lutetium-177, rhenium-188, lead-203, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227.
[0278] In some embodiments of the compound of Formula IVa, z is 0 and the [(C.sup.4)(R.sup.4)] moiety binds to the [AA] moiety via the chelating moiety C.sup.4. In some embodiments, the chelating moiety C.sup.4 forms an amide bond with the AA group.
[0279] In some embodiments of the compound of Formula IVa, z is 1 and the [(C.sup.4)(R.sup.4)] moiety binds to the [(L.sup.4)-(AA)] moiety via the L.sup.4 group, where the chelating moiety C.sup.4 binds to the L.sup.4 group.
[0280] In some embodiments, the compound of Formula IV is a compound of Formula IVb:
##STR00115##
or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is a radioisotope that is capable of covalently binding to the linker L.sup.4, the N-terminal amino acid of the fibrin-binding peptide AA, or both.
[0281] In some embodiments, R.sup.4 is selected from the group consisting of fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, and astatine-211.
[0282] In some embodiments of the compound of Formula IVb, z is 0 and the [R.sup.4] moiety binds directly to the [AA] moiety.
[0283] In some embodiments of the compound of Formula IVb, z is 1 and the [R.sup.4] moiety binds to the [(L.sup.4)-(AA)] moiety via the L.sup.4 group. In some embodiments, the R.sup.4 moiety forms a covalent bond with the L.sup.4 group. In some embodiments, R.sup.4 is fluorine-18.
[0284] In some embodiments, the compound of Formula IV is a compound of Formula IVc:
##STR00116##
or a pharmaceutically acceptable salt thereof, where the [R.sup.4] moiety binds to the [(L.sup.4)-(AA)] moiety via a covalent bond with the L.sup.4 group, wherein R.sup.4 is a radioisotope that is capable of covalently binding to the linker L.sup.4, the N-terminal amino acid of the fibrin-binding peptide AA, or both.
[0285] In some embodiments, R.sup.4 is selected from the group consisting of fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, and astatine-211. In some embodiments, R.sup.4 is fluorine-18.
[0286] In some embodiments, the compound of Formula IV is a compound of Formula IVd:
##STR00117##
or a pharmaceutically acceptable salt thereof, where the [R.sup.4] moiety binds directly to the [AA] moiety, wherein R.sup.4 is a radioisotope that is capable of covalently binding to the linker L.sup.4, the N-terminal amino acid of the fibrin-binding peptide AA, or both.
[0287] In some embodiments, R.sup.4 is selected from the group consisting of fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, and astatine-211.
[0288] In some embodiments of Formula IV, the compound is selected from the group consisting of:
##STR00118## ##STR00119## ##STR00120##
or a pharmaceutically acceptable salt thereof.
[0289] In some embodiments of Formula IV, the compound is selected from the group consisting of:
##STR00121## ##STR00122##
or a pharmaceutically acceptable salt thereof.
[0290] In some embodiments of Formula IV, the compound is:
##STR00123##
or a pharmaceutically acceptable salt thereof.
[0291] In some embodiments of Formula IV, the compound is:
##STR00124##
or a pharmaceutically acceptable salt thereof.
[0292] In some embodiments of Formula IV, the compound is selected from the group consisting of:
##STR00125##
or a pharmaceutically acceptable salt thereof.
[0293] In some embodiments of Formula IV, the compound is selected from the group consisting of:
TABLE-US-00036 Com- pound N-terminus Sequence 25
[0294] Also provided in the present disclosure is a compound of Formula V:
##STR00140##
or a pharmaceutically acceptable salt thereof, wherein C.sup.4, L.sup.4, AA, CP.sup.4, y, and z are as described in the present disclosure for compounds of Formula IV.
[0295] In some embodiments, the compound of Formula V is a compound selected from the group consisting of:
TABLE-US-00037 Comp- ound Sequence 16 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-NH.sub.2 17 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q-NH.sub.2 18 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q-NH.sub.2 19 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q-NH.sub.2 20 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 21 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-I-NH.sub.2 22 NODAGA-y-e-c-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 23 DOTAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 24 NOTA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2
Pharmaceutically Acceptable Derivatives and Compositions
[0296] In some embodiments, the compounds of the present disclosure can be formulated as a pharmaceutical composition. In some embodiments, a pharmaceutical composition comprises a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition comprises a compound of Formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition comprises a compound of Formula III, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition comprises a compound of Formula IV, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0297] As used herein, the compounds can include pharmaceutically acceptable derivatives thereof. Pharmaceutically acceptable means that the compound or composition can be administered to an animal without unacceptable adverse effects. A pharmaceutically acceptable derivative means any pharmaceutically acceptable salt, ester, or salt of an ester of the compounds of the present disclosure that, upon administration to a recipient, is capable of providing (directly or indirectly) the compounds or an active metabolite or residue thereof.
[0298] Other derivatives are those that increase the bioavailability of the compounds when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood), or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) thereby increasing the exposure relative to the parent species.
[0299] Pharmaceutically acceptable salts of the compounds of the present disclosure include counter ions derived from pharmaceutically acceptable inorganic and organic acids and bases known in the art. For example, alkali and alkaline earth metal cations; sodium; primary, secondary and tertiary amines such as ethanolamine, diethanolamine, morpholine, glucamine, N,N-dimethylglucamine, N-methylglucamine; and amino acids such as lysine, arginine and ornithine.
[0300] Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tableting lubricants, and disintegrants can be used in tablets and capsules for oral administration. Liquid preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations can be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives, such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavorings and colorants can be added to the liquid preparations. Parenteral dosage forms can be prepared by dissolving the compound of Formula I, II, III, or IV, or a pharmaceutically acceptable salt thereof in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.
[0301] A compound of Formula I, II, III, or IV, or pharmaceutically acceptable salt thereof can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically acceptable carriers, outside those mentioned herein, are known in the art; for example, see Remington, The Science and Practice of Pharmacy, 20th Ed., 2000, Lippincott Williams & Wilkins, (Editors: Gennaro, A. R., et al.).
[0302] Pharmaceutical compositions described herein can be administered by any route, including both oral and parenteral administration. Parenteral administration includes, but is not limited to, subcutaneous, intravenous, intraarterial, interstitial, intrathecal, and intracavity administration. When administration is intravenous, pharmaceutical compositions may be given as a bolus, as two or more closes separated in time, or as a constant or non-linear flow infusion. Thus, compositions of the present disclosure can be formulated for any route of administration.
[0303] In some embodiments, pharmaceutical compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. In some embodiments, the composition can also include one or more of a solubilizing agent, a stabilizing agent, and a local anesthetic (e.g., lidocaine) to ease pain at the site of the injection. In some embodiments, the composition for intravenous administration includes sucrose (e.g., 80 millimolar). In some embodiments, the ingredients will be supplied either separately, e.g. in a kit, or mixed together in a unit dosage form, for example, as a dry lyophilized powder or water free concentrate. The compositions can be stored in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent in activity units. Where the composition is administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water for injection, saline, or other suitable intravenous fluids. Where the composition is to be administered by injection, an ampule of sterile water for injection or saline can be provided as a component of the kit so that the ingredients may be mixed prior to administration.
[0304] The pharmaceutical compositions of the present disclosure containing a compound of Formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, can further contain one or more other ingredients. Examples of such ingredients include, but are not limited to, pH adjusters, stabilizing agents, decontaminating agents, and isotonicity agents. In some embodiments, the pharmaceutical composition contains one or more of acetic acid, sodium acetate, sodium hydroxide, gentisic acid, ascorbic acid, diethylene triamine pentaacetic acid (DPTA), and sodium chloride. In some embodiments, the pharmaceutical composition contains water for injection.
[0305] In some embodiments, the pharmaceutical composition comprising a compound of Formula I, II, III, or IV, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, comprises a radical scavenger. The radical scavenger can be used to prevent radiolysis. Radiolysis is the process in which the ionization of oxygen or water molecules induced by the radionuclide leads the formation of other reactive species, such as superoxide, hydrogen peroxide, hydrogen radicals, ozone and hydroxyl radicals. These reactive species can further cause damage to DNA and other cellular structures. In some embodiments, the radical scavenger is an antioxidant selected from carnosic acid, green tea extract, apigenin, diosmine, rosmarinic acid, lipoic acid, beta carotene, L-ascorbic acid (vitamin C), N-acetyl cysteine (NAC), S-tocopherol, rutin, amifostine, resveratrol, gentisic acid, and gallic acid. In some embodiments, the radical scavenger is an antioxidant selected from gallic acid, L-ascorbic acid and N-acetyl cysteine (NAC).
[0306] In some embodiments, the compositions of the present disclosure are administered to the patient in the form of an injectable composition. In some embodiments, the method of administering a compound is parenterally, meaning intravenously, intra-arterially, intrathecally, interstitially or intracavitarilly. Pharmaceutical compositions of this invention can be administered to animals including humans in a manner similar to other diagnostic or therapeutic agents. The dosage to be administered, and the mode of administration will depend on a variety of factors including age, weight, sex, condition of the patient and genetic factors, and will ultimately be decided by medical personnel subsequent to experimental determinations of varying dosage followed by imaging as described herein.
Methods of Imaging Fibrin
[0307] The compounds and compositions of the present disclosure can be used to image fibrin. In some embodiments, the fibrin is present in a tumor. In some embodiments, the tumor is cancerous. In some embodiments, the fibrin is present in a thrombus. In some embodiments, the fibrin is associated with neuroinflammation. In some embodiments, the neuroinflammation is associated with Alzheimer's disease, multiple sclerosis, or traumatic brain injury.
[0308] In some embodiments, a method for imaging fibrin in a mammal comprises administering to the mammal an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof; acquiring an image of the fibrin of the mammal using a nuclear imaging technique and acquiring an anatomical image of the mammal using magnetic resonance imaging (MRI); and overlaying said images to localize the fibrin within the anatomical image of the mammal.
[0309] In some embodiments, a method for imaging fibrin in a mammal comprises administering to the mammal an effective amount of a pharmaceutical composition comprising an compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; acquiring an image of the fibrin of the mammal using a nuclear imaging technique and acquiring an anatomical image of the mammal using magnetic resonance imaging; and overlaying said images to localize the fibrin within the anatomical image of the mammal.
[0310] In some embodiments of the method for imaging fibrin, the image of the fibrin of the mammal using a nuclear imaging technique and the image of the mammal using magnetic resonance imaging are acquired simultaneously. In some embodiments of the method for imaging fibrin, the image of the fibrin of the mammal using a nuclear imaging technique is acquired first, and the image of the mammal using magnetic resonance imaging is acquired second. In some embodiments of the method for imaging fibrin, the image of the mammal using magnetic resonance imaging is acquired first, and the image of the fibrin of the mammal using a nuclear imaging technique is acquired second.
[0311] In some embodiments of the method for imaging fibrin, the nuclear imaging technique is single photon emission computed tomography (SPECT).
[0312] In some embodiments of the method for imaging fibrin, the nuclear imaging technique is positron emission tomography (PET). In some embodiments of the method for imaging fibrin, the nuclear imaging technique is positron emission tomography in combination with computed tomography (PET-CT).
[0313] In some embodiments of the method for imaging fibrin, the mammal is a human.
[0314] In some embodiments of the method for imaging fibrin, the mammal is a rat. In some embodiments of the method for imaging fibrin, the mammal is a dog.
[0315] In some embodiments of the method for imaging fibrin, the method further comprises administering to the mammal an effective amount of a second compound or composition. In some embodiments, the second compound or composition does not target fibrin.
[0316] In some embodiments, the second compound or composition containing a second compound is a second imaging agent. In some embodiments, the second imaging agent comprises an MRI imaging agent. In some embodiments, the second imaging agent is an MRI imaging agent. For example, gadoteridol, gadopentetate, gadobenate, gadoxetic acid, gadodiamide, gadoversetamide, and gadofosveset; or a CT imaging agent selected from the group consisting of iopamidol, iohexol, ioxilan, iopromide, iodixanol, ioxaglate, metrizoate, and diatrizoate.
[0317] In some embodiments, the second compound or composition containing a second compound comprises a therapeutic radioisotope. In some embodiments, the therapeutic radioisotope is selected from the group consisting of scandium-47, copper-67, yttrium-90, iodine-131, samarium-153, terbium-161, holmium-166, lutetium-177, rhenium-188, astatine-211, lead-212, bismuth-213, radium-223, actinium-225, and thorium-227. In some embodiments, the therapeutic isotope is selected from the group consisting of yttrium-90, lutetium-177, and actinium-225. In some embodiments, the therapeutic isotope is yttrium-90. In some embodiments, the therapeutic isotope is lutetium-177. In some embodiments, the therapeutic isotope is actinium-225.
Image Overlay
[0318] Overlaying of images can be done by various means known in the art. See, for example, U.S. Pat. Nos. 7,412,279; 7,110,616; 6,898,331; 6,549,798; and 5,672,877; Rudd, J. H F. et al., J. Nucl. Med. 2008 49(6): 871-878; Slomka, P. J. et al., J. Nucl. Med. 2009 50: 1621-1630; and Jupp, B. and O'Brien, T. J., Epilepsia 2007 49: 82-89. In some embodiments, the first and second image data sets can be overlaid to determine the presence of the fibrin within the mammal. For example, the first and second image data sets can be combined to produce a third data set that includes an image of the fibrin target and an image of anatomical region where the fibrin is located. The third data set is capable of indicating the location of the fibrin, if present, within the mammal. If desired, the third data set may be displayed on a display device in order to indicate the location of the stationary target within the vascular system. The third data set may also indicate the size of the stationary target within the mammal.
Methods of Treatment
[0319] Also provided in the present disclosure are methods for treating a disease or condition associated with the presence of fibrin. In some embodiments, the disease or condition associated with the presence of fibrin is a cardiovascular disease. In some embodiments, the disease or condition associated with the presence of fibrin is cancer.
[0320] In some embodiments, the method for treating a disease or condition associated with the presence of fibrin in a mammal comprises administering to the mammal an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope. In some embodiments, the method for treating a disease or condition associated with the presence of fibrin in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope. In some embodiments, the method for treating a disease or condition associated with the presence of fibrin in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope. In some embodiments, the method for treating a disease or condition associated with the presence of fibrin in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope. In some embodiments, the method for treating a disease or condition associated with the presence of fibrin in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope. In some embodiments, the disease or condition associated with the presence of fibrin is a cardiovascular disease or condition. In some embodiments, the disease or condition associated with the presence of fibrin is a cancer. In some embodiments, the disease or condition associated with the presence of fibrin is a cerebrovascular disease (e.g., brain aneurysm, carotid stenosis, vertebral stenosis and stroke). In some embodiments, the mammal is a rat, a mouse, a dog or a pig. In some embodiments, the mammal is a human.
[0321] Also provided in the present disclosure is a method of treating cancer in a mammal. In some embodiments, the method comprises administering to the mammal an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope. In some embodiments, the method for treating cancer in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope. In some embodiments, the method for treating cancer in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope. In some embodiments, the method for treating cancer in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope. In some embodiments, the method for treating cancer in a mammal comprises administering to the mammal a pharmaceutical composition comprising a compound of Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound contains a therapeutic radioisotope.
[0322] Examples of cancers that are treatable using the compounds of the present disclosure include, but are not limited to, sarcomas, bone cancer, breast cancer, lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), genitourinary tract cancers, pancreatic cancer, liver cancers, skin cancers, melanoma (e.g., metastatic malignant melanoma, BRAF and HSP90 inhibition-resistant melanoma), cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, renal cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone refractory prostate adenocarcinoma), testicular cancer, colon cancer, gynecological cancers, uterine cancer, carcinoma of the fallopian tubes, urothelial cancer (e.g., bladder), carcinoma of the endometrium, endometrial cancer, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or urethra, carcinoma of the renal pelvis, nervous system cancers, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers. The compounds of the present disclosure are also useful for the treatment of metastatic cancers.
[0323] In some embodiments, cancers that are treatable using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, sarcoma, bladder cancer), hematological cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (including follicular lymphoma, including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma or multiple myeloma) and combinations of said cancers.
[0324] In some embodiments, cancers that are treatable using the compounds of the present disclosure include, but are not limited to, cholangiocarcinoma, bile duct cancer, triple negative breast cancer, rhabdomyosarcoma, small cell lung cancer, leiomyosarcoma, hepatocellular carcinoma, Ewing's sarcoma, brain cancer, brain tumor, astrocytoma, neuroblastoma, neurofibroma, basal cell carcinoma, chondrosarcoma, epithelioid sarcoma, eye cancer, Fallopian tube cancer, gastrointestinal cancer, gastrointestinal stromal tumors, hairy cell leukemia, intestinal cancer, islet cell cancer, oral cancer, mouth cancer, throat cancer, laryngeal cancer, lip cancer, mesothelioma, neck cancer, nasal cavity cancer, ocular cancer, ocular melanoma, pelvic cancer, rectal cancer, renal cell carcinoma, salivary gland cancer, sinus cancer, spinal cancer, tongue cancer, tubular carcinoma, urethral cancer, and ureteral cancer.
[0325] Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocytosis (ET)), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL) and multiple myeloma (MM).
[0326] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, and teratoma.
[0327] Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bronchogenic carcinoma, squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma, alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, and mesothelioma.
[0328] Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer.
[0329] Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
[0330] Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
[0331] Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors.
[0332] Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma and Lhermitte-Duclos disease.
[0333] Exemplary gynecological cancers include cancers of the uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).
[0334] Exemplary skin cancers include melanoma, basal cell carcinoma, Merkel cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids. In some embodiments, diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple-negative breast cancer (TNBC), myelodysplastic syndromes, testicular cancer, bile duct cancer, esophageal cancer, and urothelial carcinoma.
[0335] In some embodiments, the methods of the present disclosure are used to detect, treat, or detect and treat, cancers exhibiting high fibrin levels.
[0336] In some embodiments of the methods of treatment of the present disclosure, the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope, the method further comprises administering to the patient an amino acid solution. In some embodiments, the amino acid solution is used to prevent nephrotoxicity associated with radionuclide therapy. In some embodiments, the amino acid solution comprises L-lysine and L-arginine, and pharmaceutically acceptable salts and combinations thereof. In some embodiments, the amino acid solution comprises L-lysine and pharmaceutically acceptable salts thereof. In some embodiments, the amino acid solution comprises L-arginine and pharmaceutically acceptable salts thereof. In some embodiments, the amino acid solution comprises about 10 g/L to about 40 g/L of a mixture of L-lysine HCl and L-arginine HCl, such as about 12 g/L to about 35 g/L, about 16 g/L to about 32 g/L, about 20 g/L to about 30 g/L, or about 22 g/L to about 28 g/L. In some embodiments, the amino acid solution comprises about 16 g/L to about 32 g/L of a mixture of L-lysine HCl and L-arginine HCl. In some embodiments, the amino acid solution comprises between about 8 g/L and about 16 g/L of L-lysine HCl and between about 8 g/L and about 16 g/L of L-arginine HCl. In some embodiments, the amino acid solution comprises about 8 g/L, about 9 g/L, about 10 g/L, about 11 g/L, about 12 g/L, about 13 g/L, about 14 g/L, about 15 g/L, or about 16 g/L of L-lysine HCl. In some embodiments, the amino acid solution comprises about 8 g/L, about 9 g/L, about 10 g/L, about 11 g/L, about 12 g/L, about 13 g/L, about 14 g/L, about 15 g/L, or about 16 g/L of L-arginine HCl.
[0337] In some embodiments, the amino acid solution is administered intravenously. In some embodiments, the amino acid solution is administered prior to, concomitantly, after, or combinations thereof, administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope.
[0338] In some embodiments, the amino acid solution is administered prior to administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof. In some embodiments, the amino acid solution is administered about 5 minutes to about 60 minutes prior to administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, such as about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes prior. In some embodiments, the amino acid solution is administered about 30 minutes prior to administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof.
[0339] In some embodiments, the amino acid solution is administered concomitantly with the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof. In some embodiments, the amino acid solution is co-infused with the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof.
[0340] In some embodiments, the amino acid solution is administered after administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof. In some embodiments, the amino acid solution is administered immediately after or about 5 minutes to about 60 minutes after administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, such as about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes after. In some embodiments, the amino acid solution is administered about 30 minutes after administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof.
[0341] In some embodiments, the amino acid solution is administered prior to, concomitantly with, and after administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope.
[0342] In some embodiments, the amino acid solution is administered prior to, and concomitantly with administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope.
[0343] In some embodiments, the amino acid solution is administered prior to and after administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope.
[0344] In some embodiments, the amino acid solution is administered concomitantly with and after administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope.
[0345] In some embodiments of the methods of treatment of the present disclosure, the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope, the method further comprises administering to the patient an antiemetic agent. An antiemetic agent can be used to reduce nausea and vomiting associated with radiotherapy. In some embodiments, the antiemetic agent is selected from the group consisting of 5-HT.sub.3 receptor antagonists, corticosteroids, neurokinin-1 (NK-1) receptor inhibitors, prochlorperazine, metoclorpramide and cannabinoids. In some embodiments, the antiemetic agent is a 5-HT.sub.3 receptor antagonist. In some embodiments, the antiemetic agent is a NK-1 receptor inhibitor.
[0346] In some embodiments, the antiemetic agent is administered prior to, concomitantly, after, or combinations thereof, administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope.
[0347] In some embodiments, the antiemetic agent is administered prior to administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof. In some embodiments, the antiemetic agent is administered concomitantly with the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof. In some embodiments, the antiemetic agent is administered after administering the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof.
[0348] In some embodiments, the antiemetic agent is administered prior to, concomitantly, after, or combinations thereof, administering an amino acid solution, such as the amino acid solutions described in the present disclosure. In some embodiments, the antiemetic agent is administered prior to administering the amino acid solution. In some embodiments, the antiemetic agent is administered concomitantly with the amino acid solution. In some embodiments, the antiemetic agent is administered after administering the amino acid solution. Also provided in the present disclosure are methods of detecting and treating a disease or condition associated with the presence of fibrin in a mammal. In some embodiments, the method comprises detecting the disease or condition associated with the presence of fibrin in a mammal using the methods described in the present disclosure that use the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a radioisotope capable of detection using a nuclear imaging technique. In some embodiments, the method further comprises treating the disease or condition associated with the presence of fibrin in a mammal using the methods described in the present disclosure that use the compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing an effective amount of a compound of Formula I, Formula II, Formula III, or Formula IV, or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutical composition contains a therapeutic radioisotope. In some embodiments, the disease or condition associated with the presence of fibrin is cancer.
EXAMPLES
[0349] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
Example 1: Compound Synthesis and Characterization
[0350] Step aSynthesis of Unmodified Peptides
[0351] Peptides were synthesized on an automated peptide synthesizer Liberty Blue (CEM Inc.) using 1 to 12 batch reactors loaded with 0.1 mmol of commercially available Rink amide resin (?0.38 mmol/g). Standard Fmoc chemistry was used to elongate the peptide on the resin. The Fmoc was removed with a solution of 20% piperidine and 0.1 M HOBt in DMF. Each amino acid was dissolved in DMF to give a 0.2 M solution and was coupled to the peptide using a 0.5 M solution of diisopropylcarbodiimide in DMF, and 1.0 M Oxyma (or HOBt).
[0352] After the synthesis of the peptide on the resin was complete, the peptide was filtered and subsequently cleaved from the resin (TFA/TIS/MSA/2,2-(ethylenedioxy)ethane dithiol/H.sub.2O 95:2.5:2.5:2.5:2.5). The solution of fully deprotected peptide was precipitated with diethyl ether (40 mL). The peptide solid was isolated after centrifugation and then cyclized in a 1:1 mixture of DMSO/40 mMNH.sub.4OAc, pH 5. The cyclization was monitored by LC-MS (24h). The cyclic peptide was purified by reversed phase preparative TIPLC on a C-5 column using a gradient of 5% mobile phase A (0.10% TFA in water) to 600% mobile phase B (0.10% TFA in acetonitrile) over 23 minutes. The fractions of pure peptide were pooled and lyophilized to give the final peptide moiety.
[0353] Step BSynthesis of N-Terminal Modified Peptides
[0354] The N-terminus of each peptide was then modified to:
##STR00141##
See Tables 1 and 1a for the compounds (e.g., N-terminal modified peptides) prepared, where F is fluorine (Table 1) or fluorine-18 (Table 1a). All compounds possessed a C-terminal amide unless otherwise noted.
TABLE-US-00038 TABLE 1 SEQ Compound N-terminus Sequence ID NO. MW 2
TABLE-US-00039 TABLE 1a SEQ MW Compound N-terminus Sequence ID NO. 25
Example 2: Synthesis of PFP-Peptides
[0355] Unmodified peptides were prepared according to the procedure in Example 1, step A. 6-Fluoronicotinic acid-PFP (0.10 mmol) was coupled to the N-terminus of the peptides (0.02 mmol) in DMF (0.50 mL) at 40? C. overnight. The reaction was monitored by LCMS. The obtained crude compound was purified by reversed phase preparative HIPLC C-5 column (22.5?250 mm) using a gradient of 5% mobile phase A (0.1% TFA in water) to 60% mobile phase B (0.1% TFA in acetonitrile) over 23 min and pooled fractions were lyophilized to obtain the pure compound.
Example 3: Determination of Binding to Immobilized Fibrin and Soluble Fibrin Fragment DD(E) Using a Fluorescence Polarization (FP) Assay
[0356] DD(E) was prepared using a published procedure which involved partial plasmin digestion of purified fibrin gel followed by size-exclusion chromatographic purification, and purity was assessed by SDS-PAGE. Peptides modified at the N-terminus with tetramethyl-rhodamine (TRITC) dye bind to DD(E). Direct fluorescent peptide binding to DD(E) was measured by a fluorescence polarization (FP) assay. The anisotropy (r.sub.obs) of the fluorescently labeled peptides binding to DD(E) (0-20 ?M) was measured in Tris buffered saline (50 mM Tris, 100 mM NaCl and 2 mM CaCl.sub.2) at fixed compound concentrations, and the data were fit to a single site model (Eq. 1) to obtain the dissociation constant (K.sub.d) for the DD(E).Math.(fluorescent peptide) complex.
[0357] Displacement of the fluorescent peptide by non-fluorescent compound was measured to determine inhibition constants (K.sub.i). In the presence of an inhibitor, an apparent dissociation constant for the fluorescent compound (K.sub.d app) is determined using Eq. 2. The inhibition constant K.sub.i is related to K.sub.d app by Eq. 2, wherein K.sub.d is the true dissociation constant of the fluorescent compound measured in the absence of inhibitor.
[0358] Non-labeled peptide binding to DD(E) was measured by a compound displacement assay, where a DD(E)/Fl.Math.pep complex formed at fixed concentrations of DD(E) and Fl.Math.pep was titrated with increasing concentrations of unlabeled compound. The compound was assayed by mixing DD(E) (4.0 ?M, 10 ?L) and TRITC (0.1 ?M, 10 ?L) with increasing concentrations of competing peptide (0.4-100 ?M, 20 ?L) in TBS.Math.Ca with 2% DMSO in a final volume of 40 ?L. Fluorescence polarization of the samples (10 ?L, triplicate wells) in ascending concentrations was measured in a 384-well microplate (Corning flat black plate), using a Tecan Infinite 200 Pro fluorescence microplate reader equipped with fluorescence polarization filters, a 535 nm excitation filter and a 590 nm fluorescence emission filter. Average polarization (mP units) readings for each dilution of the compound of interest was converted to anisotropy (r) using Eq. 3.
[0359] The data defined a displacement curve (r.sub.obs vs. [Peptide]), and the inhibitory binding constant, K.sub.i, was determined by least squares fitting of the data (estimated uncertainty in K.sub.i?10%). See Table 2 for the K.sub.i values for the Compounds from Example 1.
TABLE-US-00040 TABLE 2 Compound K.sub.i (?M) 2 0.07 3 0.14 4 0.18 5 0.23 6 0.34 7 0.58 8 0.64 9 0.73 10 0.95 11 1.01 12 1.2 13 1.25 14 2.76 15 No displacement
Results
[0360] Affinity to soluble fibrin fragment DD(E) was screened for all the compounds from series A and C using fluorescent polarization. Compounds were compared to EP-2104R, a reference compound with validated fibrin affinity (
Example 4: Determination of Metabolic Stability Using a Rat Serum Assay
[0361] The six compounds identified in Example 3 (Compounds 2, 3, 4, 5, 6, and 7) were assayed for stability in rat plasma at 37? C. for up to 4 h. Compounds were dissolved in DMSO to a make a stock solution (0.6 mM). Plasma (995 ?L) was spiked with peptide stock solution (5 ?L). Incubations were carried at a test compound concentration of 3 ?M with a final DMSO concentration of 2.5%. The spiked plasma samples were incubated at 37? C. for 4 h. Aliquots (300 ?L) were removed at 0, 0.5, 1, 2 and 4 h and reactions were terminated by adding 600 ?L of cold acetonitrile with 0.1% formic acid containing carbutamide (25 ?g/mL) as an internal standard. Simultaneously, a plasma sample (995 ?L) containing a mixture of benfluorex, propranolol and nortriptyline (40 ?M in DMSO) control compounds was also incubated alongside each batch of test compounds and terminated similarly. In addition, matrix blanks were prepared by adding acetonitrile-containing internal standard to plasma samples without any of the analytes or control compounds. Aliquots were centrifuged at 5000?g for 5 min for protein precipitation. Following centrifugation, the concentration of the compound of interest in the supernatant was quantified by LCMS. The presence of peptides was confirmed by detection of the corresponding [(M+2)/2].sup.+. The peak area for each detected compound was measured to determine the % remaining of each compound and the result was compared with standards of pure compound and compound immediately isolated from plasma (t=0 sample). All assay samples were analyzed in triplicate. LCMS measurements were performed with a gradient elution system (5-95%) composed of water and acetonitrile with 0.1% TFA at a flow rate of 1 mL/min using a Phenomenex-C18 chromatographic column (3 ?m particle size, 4.6 mm?100 mm).
Results
[0362] Three compounds were more than 80% intact at the 2 h time point, with Compounds 7 and 6 demonstrating the greatest stability after 4 h (
Example 5: Development of F-18 Radiolabeling Conditions and Analytical Methods for the Optimized Compounds
[0363] ##STR00170##
Synthesis of 6-chloronicotinic Acid 2,3,5,6-Tetrafluorophenyl Ester (Int-1)
[0364] 6-Cl-Py-PFP (Int-1) ester was obtained by the reaction of 6-chloronicotinic acid (1.0 g, 7.1 mmol), tetrafluorophenol (TFP, 1.18 g, 7.1 mmol), in the presence of N,N-dicyclohexylcarbodiimide (DCC) (1.40 g, 6.81 mmol) in dioxane (35 mL) at room temperature for 12 h. Dicyclohexylurea (DCU) was filtered off and the solvents were removed to obtain the crude product which was crystalized from hot hexane (1.61 g, 85%). Compound identity was confirmed by .sup.1H NMR analysis.
Synthesis of N,N,N-trimethyl-5-((2,3,5,6-tetrafluorophenoxv)-carbonyl)pyridin-2-aminium Trifluoromethanesulfonate (Int-2)
[0365] A steady stream of trimethylamine gas was passed through a mixture of Int-1 (1.0 g, 3.3 mmol) in dry THE (15 mL) at room temperature for 3h. The obtained N,N,N-trimethyl-5-((2,3,5,6-tetrafluoro-phenoxy)carbonyl)pyridin-2-aminium chloride was filtered then washed with diethyl ether (100 mL) and cold dichloromethane (50 mL). The solid (0.53 g, 1.5 mmol) was suspended in DCM (50 mL) under an argon atmosphere. The solution was filtered, and volatile components were removed under reduced pressure. The residue was washed with diethyl ether (3?50 mL) and dried under vacuum to afford Int-2 (0.65 g, 41.6%). Compound identity was confirmed by .sup.1H NMR analysis.
Radiochemical Synthesis of .SUP.18.F-Py-TFP and Compound .SUP.18.F-7
[0366] [.sup.18F]Fluoride was trapped in Chromafix PS-HCO.sub.3.sup.? cartridge pretreated with 1 ml of 1 M potassium carbonate solution and 20 mL of water by passing a [.sup.18O]water containing [.sup.18F]fluoride through the cartridge. [.sup.18F]Fluoride was eluted from the cartridge using a 0.4 ml of potassium carbonate and KRYPTOFIX? 222 (Kry222) in acetonitrile:water 1:1 solution. [.sup.18F]Fluoride was dried by azeotropic evaporation at 105? C. in a stream of nitrogen by adding acetonitrile during evaporation (0.5 mL?3 times). After it was dried completely, a DMSO solution (0.3 mL) containing Int-2 (0.6 mg, 12.54 ?mol) was added to the residue and heated at 90? C. for 5 min. The reaction solution was diluted with acetonitrile:0.1% TFA solution=1:1 co-solvent and injected into Alltima C.sub.18 Semi-Preparative Column (250 mm?10 mm, 5 ?m) eluted with 0.1% TFA in acetonitrile:0.1% TFA in water=64:36 at a flow rate of 4 mL/min. .sup.18F-PFP ester was eluted between 13.0-13.5 min and it was collected in a C.sub.18 Sep-Pak Plus Cartridge. .sup.18F-PFP ester was released from the Sep-Pak using 0.9 ml of acetonitrile. DMSO (0.9 ml) containing TEA and peptide (0.5 mg, 0.36 ?mol) was added to the reaction vessel. The mixture was heated at 60? C. for 30 min. The reaction was terminated by diluting with 0.9 mL of water. The whole aliquot was injected into Gemini-NX C.sub.18 Semi-Preparative Column (250 mm?10 mm, 5 ?m) eluted with 0.1% TFA in acetonitrile:0.1% TFA in water=33:67 at a flow rate of 4 mL/min. Compound .sup.18F-7 was eluted between 12.0-12.5 min and it was collected in C.sub.18 Sep-Pak Plus Cartridge. The product was obtained using 1 mL of ethanol.
Results:
[0367] F-18 radiolabeling conditions were developed along with and analytical methods for the optimized compounds.
Example 6: Evaluation of Specificity by Competitive Binding with Fibrinogen and Plasma Proteins
[0368] A plate-based assay was developed to directly measure compound affinity to fibrin. The fibrin is immobilized and competition from soluble proteins is measured. Compounds was assayed for fibrin binding in the presence or absence of human plasma.
[0369] Fibrin Plate Preparation
[0370] Human fibrinogen (1 g) was dissolved in 30 mL of TBS buffer (50 mM Tris, 150 mM NaCl, 5 mM sodium citrate, pH 7.4) and dialyzed in a Slyde-a-Lyzer (20 000 MWCO, Cassette G2) at room temperature. After two changes of buffer, the fibrinogen was centrifuged (10 min, 2000?g) to remove undissolved material. Fibrinogen concentration was determined by measuring the absorbance at 280 nm. Stock fibrinogen solution concentration was 32.1 mg/mL. Fibrin plates with alternating rows of clotted fibrin and empty wells were prepared by polymerizing fibrinogen (100 ?L; 2.5 mg/mL) with thrombin (1 U/mL) in TBS.Math.citrate supplemented with 7 mM CaCl.sub.2 in the wells of a 96 well polystyrene microtiter plate (Immulon-II?). The uncovered plates were dried overnight at 37? C. to afford a thin film which was adsorbed to the plate, sealed with tape, and stored at ?20? C. until use. Clottable protein in individual fibrinogen batches was determined by measuring 280 nm absorbance of the soluble fraction of the solution before and after thrombin treatment, and was generally ?96% (Fibrin concentration, 7.56 ?M).
[0371] F-18 Radioactivity Based Assay Protocol for Fibrin Affinity and Specificity
[0372] An aliquot (100 ?L) from a known activity (52 ?Ci in 10 mL TBS buffer) of Compound .sup.18F-7 was added to a series of 12 known concentrations (0.01-50 ?M) of cold Compound 7 (550 ?L) in TBS buffer and mixed well to prepare 12 stock solutions. Each dilution (100 ?L) was added to both a clotted fibrin well and an empty well in duplicate. The same protocol was followed using human plasma instead of TBS buffer. Then the prepared plates were covered and incubated at room temperature for 2 h under constant agitation. An aliquot (90 ?L) was carefully pipetted into a tared test tube, from the supernatant of each well. All aliquots from supernatants as well as an aliquot (90 ?L) from each stock solution were weighed and activity of each was measured using a Cobra 5002 gamma counter. All data were decay corrected.
Data Analysis
[0373] Using the data obtained from empty wells, corresponding fibrin clotted wells and the stock solutions, the [Compound.sup.7].sub.total and [Compound.sup.7].sub.free determined. [Compound.sup.7].sub.bound for each sample was calculated as follows:
[Compound.sup.7].sub.bound=[Compound.sup.7].sub.total?[Compound.sup.7].sub.free
Using [Compound.sup.7].sub.bound and known [Fibrin].sub.total, [Compound.sup.7].sub.bound/[Fibrin].sub.total was calculated. Active binding sites (N) and dissociation constant (K.sub.d) were determined by plotting [Compound.sup.7].sub.bound/[Fibrin].sub.total vs [Compound.sup.7].sub.free. By the theoretical equation,
N and K.sub.d variables were adjusted by solver to minimize absolute error between observed and theoretical values (
Compound .SUP.18.F-7 Binding to Human Fibrin in TBS Buffer and in the Presence of Human Plasma
[0374] The similarities in the results obtained in the presence and absence of plasma proteins indicate that Compound .sup.18F-7 has a high degree of binding specificity for fibrin over fibrinogen (
Example 7: Compounds with .SUP.68.Ga, .SUP.64.Cu, or Al.SUP.18.F Chelators
NODAGA Chelators
[0375] Synthesis of (.sup.tBu).sub.3NODAGA-NHS ester: 4-(4,7-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7-triazacyclononan-1-yl)-5-(tert-butoxy)-5-oxopentanoic acid ((.sup.tBu).sub.3NODAGA-COOH, 100 mg, 0.19 mmol, 1.0 equiv.), N,N,N,N-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate, O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HBTU, 122 mg, 0.3 mmol, 1.2 equiv.) and N-hydroxysuccinimide (NHS, 37.4 mg, 0.3 mmol, 1.2 equiv.) were dissolved in acetonitrile (10 mL) and stirred at room temperature for 24 h. After removal of the solvent under reduced pressure, the resulting residue was re-dissolved in dichloromethane (10 mL) and then promptly washed with water (3?4 mL). The organic layer was dried over magnesium sulfate, filtered and evaporated to afford the title product as a white foam (141 mg, 0.22 mmol, 85%).
[0376] Syntheses of (.sup.tBu).sub.3NODAGA-peptides: (Bu).sub.3NODAGA-NHS (1.5 equiv.) was added to a solution of each peptide (1 equiv.) in dimethylformamide (1 mL). The pH of each solution was adjusted to 6.5 using diisopropylethylamine (DIPEA) and the mixtures were stirred at room temperature for 24 hours. The reaction was monitored by LCMS. Upon completion of the reaction, the (.sup.tBu).sub.3NODAGA-peptide was purified by reversed phase preparative HPLC on a C-5 column (Luna, 10?, 250?21.2 mm) using a gradient of 5% mobile phase A (0.1% TFA in water) to 60% mobile phase B (0.1% TFA in acetonitrile) over 45 minutes. Purified compound was dried under lyophilization to afford the title product.
[0377] Synthesis of Compound 16, Compound 17, Compound 18, Compound 19, Compound 20, and Compound 21: In a reaction vessels, about 10 mg of the (.sup.tBu).sub.3NODAGA-peptide were deprotected in a 1 mL solution of TFA, methanesulfonic acid, 1-dodecanethiol and H.sub.2O (92:3:3:2). Each reaction mixture was stirred for 2 h and analyzed by LCMS. Upon completion of the reaction, cold diethyl ether (15 mL) was added to precipitate out the solids. The mixture was centrifuged, and the supernatant was removed. The solids were washed with diethyl ether and dried to give the product as white solids.
[0378] Compound 16: C.sub.77H.sub.107ClN.sub.16O.sub.25S.sub.2, MS(ESI) calc: 878.3 [(M+2H)/2].sup.2+; found: 878.4.
[0379] Compound 17: C.sub.77H.sub.107ClN.sub.16O.sub.25S.sub.2, MS(ESI) calc: 878.3 [(M+2H)/2].sup.2+; found: 878.5.
[0380] Compound 18: C.sub.74H.sub.105ClN.sub.18O.sub.24S.sub.2, MS(ESI) calc: 866.2 [(M+2H)/2].sup.2+; found: 866.1.
[0381] Compound 19: C.sub.74H.sub.105ClN.sub.18O.sub.24S.sub.2, MS(ESI) calc: 866.1 [(M+2H)/2].sup.2+; found: 866.3.
[0382] Compound 20: C.sub.74H.sub.105ClN.sub.18O.sub.24S.sub.2, MS(ESI) calc: 866.1 [(M+2H)/2].sup.2+; found: 866.1.
[0383] Compound 21: C.sub.75H.sub.108ClN.sub.17O.sub.23S.sub.2, MS(ESI) calc: 857.9 [(M+2H)/2].sup.2+; found: 858.7
[0384] Compound 22: C.sub.74H.sub.105ClN.sub.18O.sub.24S.sub.2, MS(ESI) calc: 866.3 [(M+2H)/2].sup.2+; found: 866.1.
TABLE-US-00041 TABLE3 NODAGA-modifiedpeptides SEQID Compound Sequence NO. 16 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 18 NH.sub.2 17 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-Y-I-Q- 19 NH.sub.2 18 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 20 NH.sub.2 19 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-Q- 21 NH.sub.2 20 NODAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q- 22 NH.sub.2 21 NODAGA-y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-I-NH.sub.2 23 22 NODAGA-y-e-c-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 24
[0385] Radiochemical synthesis of Compounds .sup.68Ga-16, .sup.68Ga-17, .sup.68Ga-18, .sup.68Ga-19, .sup.68Ga-20, and .sup.68Ga-21, and .sup.68Ga-22: .sup.68GaCl.sub.3 (1 mCi, in 0.5 mL HCl (0.6 M)) was diluted with of pH 5, 3M sodium acetate (200 ?L) to reach pH 4.1. .sup.68GaCl.sub.3 solution (200 ?L) was combined with each NODAGA-peptide (0.1 mM 10 ?L) solution in sodium acetate (10 mM, pH 4.1) and the reaction mixture was heated at 60? C. for 10 min and purified by Sep-Pak light C.sub.18 cartridge (Waters) to remove any radiometal impurities (germanium-68 breakthrough). The radiochemical purity of the final solutions of Compound .sup.68Ga-16, Compound .sup.68Ga-17, Compound .sup.68Ga-18, Compound .sup.68Ga-19, Compound .sup.68Ga-20 (
[0386] Radiochemical synthesis of Compound .sup.64Cu-20: .sup.64CuCl.sub.2 (1 mCi), in 0.5 mL HCl (0.6 M) was diluted with 3M sodium acetate (200 ?L) to reach pH 4.5. A solution of NODAGA-Peptide 22 (0.1 mM 10 ?L) in sodium acetate (10 mM, pH 4.5) was added heated at 60? C. for 10 min. The radiochemical purity of Compound .sup.64Cu-20 was ?95% as determined by radio-HPLC analyses.
[0387] DOTAGA Chelators
[0388] Synthesis of (.sup.tBu).sub.4DOTAGA-PFP: (.sup.tBu).sub.4DOTAGA (200 mg, 0.29 mmol) and pentafluorophenol (88 mg, 0.48 mmol) were dissolved in dichloromethane (1 mL) and PS-DCC (286 mg, 0.48 mmol, 1.67 mmol/g) was added to the mixture. The reaction was stirred at room temperature and monitored by HPLC. Upon completion of the reaction, the resin was removed by filtration. The filtrates were evaporated, and the residue was dried under reduced pressure. The obtained crude (.sup.tBu).sub.4DOTAGA-PFP was used in next step without further purification. (Theoretical MW for [M+H]+=868.0, observed 867.7).
[0389] Synthesis of (.sup.tBu).sub.4DOTAGA-peptides: (.sup.tBu).sub.4DOTAGA-PFP (50 mg, 0.06 mmol) and the peptide (79.2 mg, 0.06 mmol) were dissolved in DMF (1 mL) and pH was maintained around 6.5 by adding DIPEA. The reaction was monitored by HPLC. Upon completion of the reaction, solids were precipitated with brine, washed with distilled water and dried under reduced pressure. The crude product was used in the next step without further purification. (Theoretical MW for [M+H].sup.+=2056.9, observed 2056.7).
[0390] Synthesis of Compound 23: The t-butyl esters were cleaved by stirring the (Bu).sub.4DOTAGA-peptide in a mixture of TFA, triisopropylsilane, dodecanethiol, MSA and water (92:2:2:2:2, 1 mL) at room temperature overnight. The reaction was monitored by HPLC. The reaction mixture was precipitated in cold diethylether. The solid was filtered, washed with cold diethylether and dried under reduced pressure. The crude product was dissolved in water (6 mL) and purified by reversed phase preparative HPLC on a C-18 column (Luna, 10?, 250?21.2 mm) using a gradient of 5% mobile phase A (0.1% TFA in water) to 95% mobile phase B (0.1% TFA in acetonitrile) over 30 minutes. The fractions of pure Compound 23 were combined and lyophilized to obtain a white powder.
[0391] Compound 23: C.sub.78H.sub.112ClN.sub.19O.sub.26S.sub.2, MS(ESI) calc: 1832.43 [M+H].sup.+, 916.7 [(M+2H)/2].sup.2+; found: 1831.7 [M+H].sup.+, 916.2 [(M+2H)/2].sup.2+.
TABLE-US-00042 TABLE5 DOTAGA-modifiedpeptide SEQID Compound Sequence NO. 23 DOTAGA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 25
[0392] Radiochemical synthesis of Compound .sup.68Ga-23: A SCX cartridge (100 mg, particle size m (Agilent, cat. no. 12102013)) was preconditioned first by washing with 5.5 M HCl (1 mL) and then by washing with water (10 mL). Ga-68 (3.0 mCi) was eluted with 4 mL of 0.05 M HCl and loaded on a preconditioned SCX cartridge. The cartridge was purged 10 with air and .sup.68GaCl.sub.3 was eluted with 0.3 mL of 3M NaCl solution (containing 0.1 M HCl). 0.15 mL of .sup.68GaCl.sub.3 was added to the solution of Compound 23 (25 ?L, 1.0 mM) mixed with 0.15 mL of 1.5M NaOAc buffer. The reaction mixture was heated at 90? C. for 10 min and analyzed by radio-HPLC. The radiochemical purity was ?99% as determined by radio-HPLC analysis.
[0393] Radiochemical synthesis of Compound .sup.90Y-23: A 100 ?L solution containing 0.5 mCi of .sup.90YCl.sub.3 is added to the solution of Compound 23 (25 ?L, 1.0 mM) and is mixed with 0.15 mL of pH 5 sodium acetate buffer. The reaction mixture is heated at 40? C. for 60 min and analyzed by radio-HPLC. with gamma counting of HPLC fractions.
[0394] Radiochemical synthesis of Compound 1.sup.77Lu-23: A 100 ?L solution containing 0.5 mCi of .sup.177LuCl.sub.3 is added to the solution of Compound 23 (25 ?L, 1.0 mM) and is mixed with 0.15 mL of pH 5 sodium acetate buffer. The reaction mixture is heated at 40? C. for 60 min and analyzed by radio-HPLC.
[0395] Radiochemical synthesis of Compound.sup.225Ac-23: A 100 ?L solution containing 0.1 mCi of .sup.225Ac(NO.sub.3).sub.3 and 20% L-ascorbic acid is added to the solution of Compound 23 (25 ?L, 1.0 mM) and is mixed with 0.15 mL of pH 6 Tris buffer. The reaction mixture is heated at 60? C. for 60 min and analyzed by radio-HPLC with gamma counting of HPLC fractions.
[0396] NOTA Chelators
[0397] Syntheses of (.sup.tBu).sub.2NOTA-peptide: NOTA(.sup.tBu).sub.2 (50 mg, 0.12 mmol) and HATU (68.6 mg, 0.18 mmol) were dissolved in DMF (1 mL) and the mixture was stirred at room temperature for 30 min. The peptide (181 mg, 0.13 mmol) was dissolved in DMF (1 mL) and was added and the pH was maintained at 6.5 with DIEA. The reaction was monitored by LC-MS. Upon completion of the reaction, the mixture was diluted with water (4 mL) and purified by reversed phase preparative HPLC on a C-18 column (Luna, 10?, 250?21.2 mm) using a gradient of 5% mobile phase A (0.1% TFA in water) to 95% mobile phase B (0.1% TFA in acetonitrile) over 30 minutes. The fractions of pure compound were pooled and lyophilized to obtain the final product. (Theoretical MW for [M+H]+=1771.5, observed 1771.7).
[0398] Synthesis of Compound 24: In a reaction vessel, about 35 mg of the (.sup.tBu).sub.2NOTA-peptide was deprotected in a 1 mL solution of TFA, methanesulfonic acid, 1-dodecanethiol, triisopropylsilane and H.sub.2O (92:2:2:2:2). The reaction mixture was stirred for 2 h at room temperature, and analyzed by LCMS. Upon completion of the reaction, cold diethyl ether (15 mL) was added to precipitate out the solids. The mixture was centrifuged, and the supernatant was removed. The solids were washed with diethyl ether and dried to give the product as a white solid. The crude product was dissolved in water (5 mL) and purified by reversed phase preparative HPLC on a C-18 column (Luna, 10?, 250?21.2 mm) using a gradient of 5% mobile phase A (0.1% TFA in water) to 95% mobile phase B (0.1% TFA in acetonitrile) over 30 minutes. The fractions of pure Compound 24 were pooled and lyophilized to obtain a white powder.
[0399] Compound 24: C.sub.71H.sub.101ClN.sub.18O.sub.22S.sub.2, MS(ESI) calc: 1659.3 [M+H].sup.+, 830.1 [(M+2H)/2].sup.2+; found: 1659.7 [M+H].sup.+, 829.7 [(M+2H)/2].sup.2+.
TABLE-US-00043 TABLE4 NOTA-modifiedpeptide SEQID Compound Sequence NO. 24 NOTA-Y-e-C-Hyp-Y(3-Cl)-G-L-C-H-I-q-NH.sub.2 26
[0400] Radiochemical synthesis of Compound .sup.68Ga-24: A SCX cartridge (100 mg, particle size 40 ?m (Agilent, cat. no. 12102013)) was preconditioned first by washing with 5.5 M HCl (1 mL) and then by washing with water (10 mL). Ga-68 (3.2 mCi) was eluted with 4 mL of 0.05 M HCl and loaded onto the preconditioned SCX cartridge. The cartridge was purged with air and .sup.68GaCl.sub.3 was eluted with 0.3 mL of 3 M NaCl solution (containing 0.1 M HCl). .sup.68GaCl.sub.3 (0.15 mL) was added to a solution of Compound 24 (25 ?L, 0.6 mM) in NaOAc buffer (1.5 M, 0.15 mL, pH 4.5). The reaction mixture was heated at 90? C. for 10 min and analyzed by radio-HPLC. The radiochemical purity of the final product was ?98%.
[0401] Radiochemical synthesis of Compound A.sup.18F-24: A sep-Pak Light Accell Plus QMA cartridge (Waters) was pre-conditioned by passing 10 mL of 0.4 M KHCO.sub.3 followed by 10 mL of DI water. .sup.18F (2.0 mCi, 200 ?L) was loaded onto the cartridge and washed with DI water (5 mL) and was eluted from the column with KHCO.sub.3 (400 ?L) and acidified to pH 4.0 with acetic acid. An AlCl.sub.3 stock solution (2 mM, in pH 4, in 0.1 M sodium acetate buffer) was prepared and 300 ?L were mixed with the .sup.18F solution. A solution of Compound 24 (2 mM, 300 ?L) in 0.1 M NaOAc was added and heated at 115? C. for 15 min and analyzed by radio-HPLC (Ultra AQ, C.sub.18, 5 m, 250?4.6 mm) using a gradient of 5% mobile phase A (50 mM ammonium acetate in water) to 95% mobile phase B (10% 50 mM ammonium acetate in water and 90% acetonitrile). The radiochemical purity of the product was 80%. After purification by HPLC, the radiochemical purity was >95%.
Example 8: Evaluation of Fibrin-Specific Compounds in Rat Model of Carotid Endothelial Injury
[0402] Rat carotid endothelial injury model in vivo studies were conducted, wherein the common carotid artery is isolated and crushed briefly with a hemostat, resulting in mural thrombus formation at the site of the crush. The vessel wall fibrin is then imaged with our PET compounds. All six compounds were evaluated in this model.
[0403] Adult male Wistar rats were anesthetized by isoflurane (1-2% in medical air). Body temperature was maintained at 37? C. using a thermo-regulated heating pad. The right femoral vein and artery were cannulated for compound injection and blood sampling, respectively. Endothelial injury was induced by crush injury to the right common carotid artery (1-2 cm proximal to the carotid bifurcation) by clamping the vessel with a hemostat for 5 minutes. Immediately following the surgical procedures, rats were placed in a micro-PET/CT scanner. Compound (200-600 ?L) was injected, PET-CT images were acquired, and blood samples were drawn from the femoral artery prior to compound injection and at 2, 5, 10, 15, 30, 60, 90, 120 min post injection. Tissues were harvested at the end for ex vivo analyses.
Example 9: Blood Analysis to Determine Blood Clearance of Compounds in Rats
[0404] Blood samples were drawn from prior to probe injection and at 2, 5, 10, 15, 30, 60, 90, 120 min post injection. Each blood sample was weighed and counted using a gamma-counter. The activity in each sample was calculated as percent injected dose (% ID) per gram of tissue. Compounds .sup.68Ga-19 and .sup.68Ga-20 demonstrated faster blood clearance and better metabolic stability relative to the other compounds in the study (
Example 10: Functional Compound Assay Analysis for Evaluation of the Fraction of Intact Compound Circulating at Each Time Point
[0405] Plasma was separated (at t=10 and 60 min) and the plasma samples were incubated with fibrin immobilized in a well plate for 2 h at RT. After incubation, the counts in the supernatant in both the fibrin-containing and empty wells were measured on a gamma counter and divided by the weight of plasma to determine the concentration of unbound probe, [unbound], and total probe, [total], respectively. The amount of .sup.68Ga containing species bound to fibrin, [bound], was calculated from [bound]=[total]-[unbound]. As a positive control, an aliquot of the dose was spiked into blood plasma and used to estimate the total possible fibrin binding in the assay (% bound at t=0). The amount of functional probe in the blood at time t was determined by taking the ratio of the % bound to fibrin at time t compared to the % bound at t=0, and multiplying this ratio by the measured total .sup.68Ga % ID/g in the blood. By measuring the activity in a well plate containing fibrin and comparing it to the activity in a well plate without fibrin, the percentage of activity bound to fibrin was estimated. This % bound is compared to the % bound measured when pure compound is spiked into fresh plasma (
Example 11: Radio-HPLC Analysis of Blood for Identification of Metabolites
[0406] Aliquots of the 15 and 90 min plasma samples were injected into a HPLC and fractions were collected each 30 seconds. The fractions counted were compared to pure compound injected into the same column in order to identify the number of metabolites and the fraction of intact compound circulating at each time point. Unexpectedly, Compound .sup.68Ga-16 rapidly formed metabolites after injection while other compounds of similar structures stayed intact (
Example 12: Biodistribution
[0407] The injured carotid, the contralateral carotid, and all the organs were removed, weighed, and counted using a gamma-counter. The activity in the various organs was expressed as percent injected dose (% ID) per gram of tissue (
Example 13: Autoradiography
[0408] The injured ipsi- and the contra-lateral carotid arteries were placed on a multipurpose film and imaged using a Perkin-Elmer Cyclone Plus Storage Phosphor system. Additional in vivo studies were conducted using PET imaging with two Compounds .sup.68Ga-19 (n=6 rats) and .sup.68Ga-20 (n=9 rats) (
[0409] Compound .sup.68Ga-20 was also successfully validated in a rabbit model of high risk plaque (plaque-rupture model). Mean SUV values, TBR.sub.vc and TBR.sub.m were compared across all rabbits after in vivo PET.
Example 14: Ex Vivo Studies of Human Carotid Endarterectomy Specimens
[0410] Twelve discarded surgical specimens from asymptomatic patients who underwent elective carotid endarterectomy at Massachusetts General Hospital were obtained and used in ex vivo studies described herein. Samples were processed for histology, autoradiography, and probe binding assay as described above (Examples 6 and 13).
[0411] Discarded surgical specimens were embedded in optimal cutting temperature compound, snap-frozen, and stored at ?80? C. before further analysis. Alternating consecutive cryosections were processed for histology and autoradiography; triplicate tissue samples with 50 ?m gap in between were used for these experiments. The remaining tissue samples were processed for functional probe assay.
[0412] For histology: the specimen were fixed using 4% paraformaldehyde containing 30% sucrose. The rostral part of each segment was embedded in optimal cutting temperature compound for cryosectioning for histology (Carstairs' staining). The remaining aortic segments were cut open for gross pathology. Carstairs' staining was used to differentiate fibrin (bright red), collagen (bright blue), erythrocytes (yellow to orange), platelets (gray-blue to navy), and muscle (red). Sections were inspected using a microscope (Nikon Eclipse 50i, Kodak Scientific Imaging System), and digital images were acquired using a camera (SPOT 7.4 Slider RTKE, Diagnostic Instruments) connected to a computer.
[0413] For autoradiography, three 30 ?m-thick sections were incubated with .sup.68Ga-20 or non-fibrin binding control probe .sup.68Ga-22 for 45 minutes on a lab shaker at room temperature. Autoradiography was performed after three washes of PBS. The exposure time was 2 minutes.
[0414] For functional probe assay, samples were thawed at room temperature, weighed (8-15 mg per sample), cut into duplicates, and placed into tubes containing 111-148 kBq (3-4 ?Ci).sup.68Ga-20 or the non-fibrin binding control probe .sup.68Ga-22 in 1 mL PBS. The mixture was shaken for 45 minutes at room temperature. After centrifugation, supernatant (sup-1) was removed, kept for further analysis, and tissue samples were washed with PBS (1 mL); this procedure was repeated twice for each sample. Wash solutions (wash-1 and wash-2) were kept for further analysis. Activities in tissue samples and solutions sol-1, wash-1, and wash-2 were measured on a gamma counter. Percent uptake was calculated as follows:
% uptake=[(activity in tissue)/total activity (tissue+sup-1+wash-1+wash-2)]?100
Results:
[0415] Both autoradiography (
OTHER EMBODIMENTS
[0416] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.